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Abstract 
Resistance to apoptosis is a hallmark of tumour cells. It constitutes an important 
clinical problem since chemotherapy and irradiation act primarily by inducing 
apoptosis. Compounds inhibiting proteasomal activity are able to selectively induce 
tumour cell apoptosis and a growing body of evidence suggests the up-regulation of 
NOXA (a BH3-only protein) upon proteasome inhibition to be one of the essential 
events. However, the underlying molecular mechanisms giving rise to the selective 
NOXA up-regulation in tumour cells is poorly understood.  
The current work shows that in cells susceptible to proteasome inhibition NOXA 
protein was significantly less stable and continuously degraded by the Ubiquitin-
Proteasome System (UPS). Amongst others, the degradation of substrates by the 
UPS is regulated by E3-ubiquitin ligases and deubiquitylating enzymes (DUBs). In 
the current work UCH-L1 was identified as a responsible DUB of NOXA, which was 
epigenetically silenced in tumour cells susceptible to proteasome inhibition. UCH-L1 
binds and stabilizes NOXA by removing the Lys48-linked polyubiquitin chains that 
normally mark NOXA for proteasomal degradation. In line with these observations, 
increased UCH-L1 expression correlated with increased NOXA protein expression in 
human melanoma and colorectal cancer patient samples. As one of the genes 
responsive to genotoxic stress, NOXA has been considered as the BH3-only protein 
to be involved in the fine-tuning of apoptosis. Correspondingly, the current work 
demonstrates that UCH-L1 expression is important for DNA-damage induced 
apoptosis. Down-regulation of UCH-L1 results in decreased susceptibility to DNA 
damage-induced apoptosis accompanied by a decreased NOXA accumulation. 
Taken together, the current work identified UCH-L1 as an important component of 
the DNA damage response that impacts on the susceptibility of cancer cells toward 
chemotherapy by stabilizing NOXA. 
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Zusammenfassung 
 
Tumore zeichnen sich unter anderem durch eine Apoptoseresistenz aus, die ein 
gravierendes Problem in der Krebsbehandlung darstellt, da sowohl Chemotherapie 
als auch Bestrahlung primär über die Induktion der Apoptose wirken.  
Inhibitoren des humanen 26S Proteasoms sind beschrieben, selektiv in Tumorzellen 
Apotose zu induzieren.  Essentiell für die Induktion der Apoptose nach Behandlung 
mit Proteasominhibitoren ist die Akkumulation des pro-apoptotischen "BH3-only"-
Proteins NOXA, wobei der Mechanismus nicht vollständig aufgeklärt ist.  
Die vorliegende Arbeit zeigt, dass die Fähigkeit von Proteasominhibitoren, Apoptose 
zu induzieren unter Tumourzellen von verschiedenen Individuen stark variiert. 
Außerdem wurde gezeigt, dass die Stabilität des essentiellen "BH3-only"-Proteins 
NOXA ebenfalls unter Tumourzellen von verschiedenen Individuen stark variiert. In 
Tumourzellen die nach Proteasominhibition Apoptose induzieren ist die Stabilität von 
NOXA stark verringert. Es wurde demonstriert, dass die verringerte Stabilität von 
NOXA die Folge einer verstärkten Ubiquitinierung und somit Degradation durch das 
Ubiquitin-Proteasome System (UPS) ist. Die Degradation von Proteinen durch das 
UPS wird unter anderem durch E3-Ubiquitin-Ligasen und deubiquitinierende Enzyme 
(DUB) reguliert. In der vorliegenden Arbeit wurde Ubiquitin-C-terminal hydrolase-L1 
(UCH-L1) als spezifische DUB von NOXA identifiziert. In Tumourzellen, die eine 
verringerte Stabilität von NOXA aufweisen wurde UCH-L1 nicht exprimiert. Als 
direkter Interaktionspartner von NOXA war UCH-L1 in der Lage, NOXA zu 
deubiquitinieren und somit zu stabilisieren. In Übereinstimmung mit biochemischen 
und zellbiologischen Ergebnissen zeigten Expressionsanalysen von NOXA und 
UCH-L1 in Geweben von 81 Melanom- und 26 Coloncarcinompatienten ebenfalls 
eine Korrelation der Expression. Gewebe in den denen UCH-L1 exprimiert war, 
wiesen eine erhöhte Expression von NOXA auf.  
NOXA ist ursprünglich als ein Protein beschrieben, das für die zelluläre Antwort zu 
genotoxischem Stress wichtig ist, indem es an der Feinabstimmung der 
mitochondrialen Membranpermeabilisierung (MOMP) beteiligt ist. Die vorliegende 
Arbeit zeigt, dass auch UCH-L1 für den Ablauf von Apoptose nach DNS-Schädigung 
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wichtig ist, indem es die Stabilität von NOXA kontrolliert.. Herunterregulation der 
UCH-L1 Expression in UCH-L1-exprimierenden Tumorzellen verringerte deren 
Fähigkeit nach Schädigung der DNS Apoptose zu induzieren. Dies war die Folge 
einer verringerten Fähigkeit NOXA zu akkumulieren.  
Zusammenfassend wurde in dieser Arbeit UCH-L1 als spezifische DUB von NOXA 
identifiziert. Durch die Fähigkeit NOXA zu stabilisieren spielt UCH-L1 in der 
zellulären Antwort auf DNS-Schädigung eine entscheidende Rolle und beeinflusst die 
Sensitivität von Tumorzellen gegenüber Chemotherapie.   
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Abbreviations 
Only abbreviations are listed that have not been described in the text 
 
α    anti 
°C    Degree Celsius 
µg    Microgramm 
µl    Microliter 
µM    Micromolar 
aa     amino acids 
ATP    adenosine triphosphate 
bp     basepares 
BSA     bovine serum albumin 
C-terminal    carboxyterminal 
Da, kDa    Dalton, Kilodalton 
DMSO    Dimethylsulfoxid 
DNA     Deoxyribonucleic acid 
ds    double stranded 
DTT     Dithiothreitol  
E.coli     Escherichia coli 
DTT     Dithiothreitol 
EDTA    ethylene diamine tetraacetic acid 
et al.    et alteri /-a /-um (and others) 
FCS     fetal calf serum 
Fig.    figure 
GFP     green fluorescent protein 
FITC     fluorescein-5-isothiocyanat 
HEPES    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His, H    Histidine 
HRP     horse radish peroxidase 
IgG     Immunglobuline G 
K     Lysine 
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kb     kilo base 
kDa     kilo dalton 
N     Asparagin 
NaCl    Sodium chloride   
nm     Nanometer 
N-terminal    aminoterminal 
MEFs    mouse embryonic fibroblasts 
MW    molecular weight  
ORF     open reading frame 
ON     over night 
PBS     phosphate buffered saline 
PCR     polymerase chain reaction 
pH     potentium hydrogenii (lat.) 
pmol     Picomol  
RT     room temperature 
SDS     sodiumdodecylsulfat 
SDS-PAGE    SDS polyacrylamid gel electrophoresis 
Tab.    table 
Tris/HCl    tris[hydroxymethyl]aminoethane 
V     Volt 
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1 Introduction 
1.1 Hallmarks of cancer 
The formation of malignant tumours is characterized by defects in cell proliferation 
and homeostasis eventually resulting in overgrowth and thereby loss of function of 
healthy tissue.  
It is thought that the transformation of a healthy cell into a malignant cell is a 
multistep process with alterations in major signalling pathways. The vast majority of 
cancer cell genotypes is a manifestation of eight essential alterations in cell 
physiology that collectively dictate malignant growth: self-sufficiency in growth 
signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed 
cell death (apoptosis), limitless replicative potential, sustained angiogenesis, tissue 
invasion and metastasis, reprogramming of energy metabolism and evading immune 
destruction (Hanahan and Weinberg, 2000, 2011). Underlying those alterations are 
dynamic disorders within the genome. Previous analyses of malignant tissues have 
identified several genes, which are involved in malignant formation, either by a gain–
of-function, referred to as oncogenes, or by a loss-of-function, referred to as tumour 
suppressors (Weinberg, 1996).  
Furthermore, tumours are more than just a vast array of uncontrolled proliferating 
cancer cells. Rather they are a complex construction composed of multiple distinct - 
also non-malignant - cell types, which facilitate the acquisition of the hallmarks of 
cancer by forming the tumour microenvironment. How developing tumours acquire 
the hallmarks of cancer is a diverse process leading to hundreds of distinct types of 
cancer and numerous subtypes of tumours within specific organs. Nevertheless, the 
recognition of these common hallmarks enabled the introduction of mechanism-
based targeted therapies, such as the reactivation of the apoptotic machinery 
(Hanahan and Weinberg, 2011). 
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1.2 Apoptosis 
Apoptosis describes programmed cell death or cell suicide (Kerr et al., 1972). It is 
crucial for sculpting the embryo, maintaining tissue homeostasis, shaping the 
immune repertoire, terminating immune responses and restricting the progress of 
infections. The average adult human body generates approximately 60 billion cells 
per day, and as a consequence an equal number of cells must die by apoptosis to 
maintain tissue homeostasis. Disturbed regulation of this vital physiological process 
can result in numerous diseases including autoimmunity, degenerative disorders as 
well as cancer. Resistance to apoptosis can also permit tumour cells to escape from 
immune surveillance.(Strasser et al., 1991; Watanabe-Fukunaga et al., 1992), (Barr 
and Tomei, 1994; Thomson, 1995) (McDonnell and Korsmeyer, 1991; Strasser et al., 
1990). Moreover, because chemotherapy and irradiation act primarily by inducing 
apoptosis, defects in the apoptotic pathway contribute to the resistance of cancer 
cells to conventional therapy, which constitutes an important clinical problem (Kerr et 
al., 1994). 
The process of a programmed cell death was first described by Carl Vogt in 1842 
(Vogt, 1842). The German scientist studied the development of tadpoles, and 
described the programmed cell death as a crucial step in the embryonic development 
of tadpoles. The drawings by Walther Flemming in 1885 provided the first 
morphological description of the programmed cell death. Those drawings clearly 
show cell shrinkage, nuclear fragmentation and apoptotic body formation, which are 
by now accepted hallmarks of apoptosis. However, a more detailed description was 
lacking until 1972 when Kerr, Wyllie and Curie were able to distinguish the 
programmed cell death and the traumatic or necrotic cell death (Necrosis) by electron 
microscopic analysis (Kerr et al., 1972). They introduced the word "apoptosis" 
(ἁπόπτωσισ) which in Greek describes the "dropping off" or "falling off" of petals from 
flowers, or leaves from trees. 30 years later, in 2002 Bob Horvitz received the Nobel 
Prize in Physiology and Medicine for his pioneering work unravelling the fundamental 
aspects of the biology of apoptosis, using the nematode Caenhorhabditis elegans (C. 
elegans) as a model system (Horvitz, 2003a, b).  
Morphological apoptosis is characterized by defined cellular changes. These 
changes include blebbing, cell shrinkage, nuclear fragmentation, chromatin 
condensation, chromosomal DNA fragmentation (Wyllie et al., 1980) and the 
Introduction 
 3 
exposure of phosphatidyl-serines on the plasma membrane (Fadok and Henson, 
1998). Apoptosis produces cell fragments called apoptotic bodies that are engulfed 
and quickly removed by phagocytic cells before the contents of the cell can spill and 
cause damage. In contrast, necrotic cell death is characterized by cell swelling, 
chromatin digestion, and disruption of the plasma membrane and organelle 
membranes (Enari et al., 1998; Fadok and Henson, 1998; Kerr et al., 1972; Wyllie et 
al., 1980). Leaky necrotic cells release intracellular contents, thereby causing 
inflammation (Fig. 1.1). While apoptosis often provides beneficial effects to the 
organism, necrosis is almost always detrimental and can be fatal. Necrosis is caused 
by factors external to the cell or tissue, such as infections, toxins, or trauma. In 
contrast, apoptosis is a naturally occurring cause of cellular death and tightly 
regulated by intracellular signalling pathways in response to cellular stress (Ellis and 
Horvitz, 1986; Vaux et al., 1988). 
 
 
Figure 1.1 | Morphology of apoptosis and necrosis.  Apoptosis is 
characterized by nuclear and DNA fragmentation, cell shrinkage and the 
formation of apoptotic bodies. Phagocytic cells engulf apoptotic bodies without 
activating the inflammatory response (right). Necrotic cell death is characterized 
by cell swelling, chromatin digestion and disruption of the plasma membrane 
resulting in the release of intracellular material and the activation of the 
inflammatory response (left) (Goodlett and Horn, 2001). 
Goodlett et. al, 2001, modified
The cell membrane rubtures 
and releasesthe cell´s content;
cytotoxic components spill out 
from the membrane inducing 
damage and immflamation
Chromatin condenses, the cell shrinks 
and fragments into small membrane 
bound apoptotic bodies which are 
phagocytized by adjoining cells.
Organelles
Nucleus
Blebs Blebs
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The DNA fragments, chromatin and 
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pathways activate the self-removal
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1.2.1 Apoptotic signalling 
In principle, there are two alternative pathways that initiate apoptosis: one is 
mediated by death receptors on the cell surface — referred to as the "extrinsic 
pathway"; the other is mediated by mitochondria — referred to as the "intrinsic or 
mitochondrial pathway". The initiation of extrinsic and mitochondrial apoptotic 
pathways occur by engagement of extracellular "death receptors" and intracellular 
stress (e.g. inadequate cytokine support, diverse types of cellular damage), 
respectively (Strasser et al., 2000).  
Both pathways involve the activation of cysteine aspartidyl-specific proteases 
(caspases) - the main executioners of the apoptotic process (Kumar and Lavin, 1996; 
Nicholson and Thornberry, 1997).  
1.2.1.1 Caspases 
Caspases cleave cellular substrates and thus initiate the biochemical and 
morphological changes that are characteristic of apoptosis. For instance, caspases 
process the inhibitor of the caspase-activated-DNase (CAD) resulting in active CAD 
that is responsible for DNA fragmentation (Sakahira et al., 1998). Moreover caspases 
induce the processing of the nuclear protein lamin and the poly (ADP-ribose) 
polymerase (PARP), which plays an important role in DNA damage repair, and its 
processing serves as a marker of ongoing apoptosis (Masson et al., 1995). 
Furthermore, regulators of the cytoskeleton and adhesion proteins are processed by 
caspases resulting in cell shrinkage and disruption of the extracellular matrix 
(Sanghavi et al., 1998).  
Caspases are a highly conserved family of cysteine proteases that cleave their 
substrates specifically after certain aspartate residues (Alnemri et al., 1996). Based 
on their intracellular function, caspases can be divided into three subgroups: cytokine 
activators (caspase 1, 4, 5, 11, 12, 13, 14), the initiator caspases (caspase 2, 8, 9, 
10) and the effector caspases (caspase 3, 6, 7), while only initiator- and effector 
caspases play a role during apoptotic signalling (Denault and Salvesen, 2002). 
Caspases are constitutively expressed in most cell types and reside as zymogenes in 
the cytosol (Nicholson, 1999). Structurally caspases consist of an amino-terminal (N-
terminal) pro-domain, a large and a small subunit (Denault and Salvesen, 2002). 
Upon activation, the large and the small subunit are separated by proteolytic 
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cleavage, and in a second step the pro-domain is removed.  Active caspases form 
tetramers consisting of two small and two large subunits, which form two active sites 
(Widlak et al., 2003). The large subunit comprises the catalytic cysteine residue 
(Walker et al., 1994; Wilson et al., 1994) (Fig. 1.2). Some caspases also possess 
interaction domains such as the caspase associated recruitment domain (CARD) or 
the death effector domain (DED) (Ashkenazi and Dixit, 1998).  
The activation of the caspase cascade is a point of no return. Once initiator caspases 
are activated, they activate the effector caspases by proteolytic cleavage resulting in 
degradation of the apoptotic substrates (Nicholson and Thornberry, 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 | Activation of caspases. Caspases consist of a pro-domain, a 
large and a small subunit. Upon activation the large and small subunit are 
separated by proteolytic cleavage and the pro-domain is removed (Denault and 
Salvesen, 2002). Active caspases form dimers comprising two large and two 
small subunits that form two active sides with the catalytic cystein residing in the 
large subunit (Widlak et al., 2003). 
1.2.1.2 The extrinsic apoptotic signalling pathway  
The extrinsic apoptotic-signalling pathway plays an important role during the 
development of T- and B-cells and is essential for the immune response.  
Extrinsic apoptotic signalling is initiated through ligand binding (e.g. TNFα, CD95) to 
the extracellular domain of a death receptor of the TNF superfamily such as TNFR1 
or CD95/FAS receptor (Ashkenazi, 2002). Characteristic for death receptors are a 
large subunit
small subunit
calalytic cystein
N-terminal pro-domain
proteolytic
processing
proteolytic
processing
dimerization
activation
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cytosolic death domain (DD) and a death effector domain (DED) that upon activation 
initiate receptor-oligomerization and interaction with adaptor proteins (e.g. TRADD 
(TNF associated death domain) or FADD (Fas-associated-death-domain)), 
respectively. The resulting death inducing signalling complex (DISC) in turn leads to 
the recruitment of several pro-caspase 8 - or in some cases also pro-caspase 10 - 
molecules through their DED. The proximity of the zymogens provokes their 
dimerization and subsequent autocatalysis (Boatright et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 | The extrinsic apoptotic signalling pathway. Upon binding of a 
death ligand (e.g. FAS, TRAIL, TNFa) the death inducing signalling complex 
(DISC) is formed, resulting in active caspase 8 (casp8). Caspase 8 directly 
activates caspase 3 (casp3) or indirectly by engaging the mitochondrial 
apoptotic signalling pathway via members of the pro-apoptotic BH3-only family. 
Active caspase 3 cleaves the apoptotic substrates and apoptotic cell death 
occurs.  
-
apoptotic substrates
FADD
DDDDDD
DEDDEDDED DISC
(FAS , TR AIL , TNFa)
death 
receptors
pro-casp8
casp8
casp3
mitochondrial apoptotic 
signalling pathway
BH3-
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Alternatively, the extrinsic apoptotic pathway can be triggered by cytolytic T-cells or 
natural killer (NK) cells with the release of perforine and granzyme B. Perforine-
release results in extracellular membrane permeabilization of the target cell and 
allows granzyme B to enter the cell (Lord et al., 2003). 
Active caspase 8 or intracellular granzyme B proteolytically activate effector 
caspases such as caspase 3 irrevocably resulting in apoptotic cell death. Besides the 
direct activation of caspase 3, caspase 8 and granzyme B induce the mitochondrial 
apoptotic signalling pathway through engagement of pro-apoptotic BH3-only proteins 
(Fig. 1.3) (Luo et al., 1998; Wei et al., 2000). 
1.2.1.3 Intrinsic/mitochondrial apoptotic signalling pathway 
The intrinsic apoptotic signalling pathway is also often referred to as the 
mitochondrial apoptotic signalling pathway since the release of pro-apoptotic 
molecules from the mitochondrial inter-membrane space is the central event. The 
release of mitochondrial pro-apoptotic molecules is regulated by pro- and anti-
apoptotic members of the Bcl2 protein family (Kluck et al., 1997; Vander Heiden et 
al., 1997; Yang et al., 1997). Upon intracellular stress, pro-apoptotic Bcl2 proteins 
(BH3 only proteins, see 3.2) are activated which in turn leads to the activation of the 
pro-apoptotic multi-domain proteins BAX and BAK. Upon activation, BAX and BAK 
undergo conformational changes and form homodimers (Hsu et al., 1997) that are 
thought to form pores in the mitochondrial outer membrane. This event is also 
referred to as mitochondrial outer membrane permeabilization (MOMP).  
Another model states that induction of MOMP might occur by direct interaction of 
BAX and BAK with channels in the outer mitochondrial membrane such as VDAC 
(voltage dependent anion channel) or PTPC (permeabilization transition pore 
complex), rather than forming pores by themselves. Although a lot of research has 
been conducted in this field, the precise mechanism of MOMP is still not understood 
(Tait and Green, 2010). However, there is agreement about the fact that Bcl2-
mediated MOMP subsequently results in the release of pro-apoptotic molecules such 
as cytochrome c and SMAC (second mitochondrial activator) (Newmeyer and 
Ferguson-Miller, 2003). Cytosolic cytochrome c binds in an ATP or dATP-dependent 
manner to APAF1 resulting in the recruitment of pro-caspase 9 molecules. The 
generated multiprotein complex, referred to as apoptosome, triggers the activation of 
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the initiator caspase 9. The initiator caspase directly activates the executioner 
caspase 3 and mediates subsequent continuation of apoptosis (Green, 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 | The mitochondrial apoptotic signalling pathway. The 
mitochondrial apoptotic signalling pathway is induced upon intracellular stress. 
This leads to the activation of pro-apoptotic BH3-only proteins and BAX/BAK-
dependent MOMP with the release of cytochrome C (Cyt C) from the 
mitochondrial intermembrane space. Cyt C forms a complex, the apoptosome, 
with ATP, APAF1 and pro-caspase 9 (pro-casp9), resulting in the activation of 
caspase 9 (casp9). Caspase 9 activates caspase 3 (casp3) and apoptosis 
proceeds. The mitochondrial apoptotic signalling pathway can also be engaged 
by the extrinsic pathway. Active caspase 8 (casp3) cleaves and thereby 
activates the BH3-only protein BID, ultimately resulting in MOMP. 
As mentioned above the mitochondrial apoptotic signalling pathway is also induced 
upon activation of the extrinsic pathway. Active caspase 8 or granzyme B can directly 
cleave BID thereby forming the active tBID (truncated BID), which in turn activates 
BAX and BAK resulting in MOMP (Fig. 1.4) (Luo et al., 1998; Wei et al., 2000). 
Depending on the cell type, this interference of both signalling pathways either 
resembles an amplification loop or is essential for the progression of apoptosis. Cells 
which can undergo apoptosis independently of MOMP are referred to as type I cells 
B AX
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(e.g. hepatocytes, pancreatic cells) and cells which depend on MOMP to effectively 
induce apoptosis are referred to as type II cells (e.g. lymphocytes) (Yin et al., 1999).  
1.3 The Bcl2 protein family 
The Bcl2 protein family regulates stress-induced apoptosis by an evolutionary highly 
conserved mechanism found in species as distantly related as humans and 
nematodes. The family consists of anti-apoptotic (e.g. BCL2, BCLxl, BCLw, A1) and 
two groups of pro-apoptotic members: the multidomain or BAX/BAK like proteins 
(e.g. BAK, BAX) and the BH3-only proteins (e.g. BIM, BID, PUMA, BAD, NOXA). 
Members of the Bcl2 protein family share at least one conserved Bcl2 homology 
domain (BH domain), which is characterized by several α-helical segments. The BH-
domain does not possess enzymatic activity but it allows pro- and anti-apoptotic 
members to bind to and to inhibit each other (Adams and Cory, 1998; Cory and 
Adams, 2002). Binding affinity assays using BH3-only peptides revealed that not all 
pro- and anti-apoptotic Bcl2 proteins can antagonize each other, but the affinity 
differs within the family (Fig. 1.5). Thus, level and composition of pro- and anti-
apoptotic Bcl2 proteins determine whether intracellular stress results in apoptotic cell 
death or not (Chonghaile and Letai, 2008).  
 
  
 
 
 
 
 
 
 
 
Figure 1.5 | Binding-pattern of pro- and anti-apoptotic members of the 
Bcl2 protein family. The BH3-only proteins BIM, BID, PUMA and BMF can 
bind and antagonize all anti-apoptotic Bcl2 proteins. In contrast, BAD can only 
bind BCL2, BCLxl and BCLw, and NOXA is restricted in binding to MCL1 and 
A1.  
Anti-apoptotic members of the Bcl2 protein family possess four BH domains and a 
carboxy-terminal transmembrane domain (TM), which targets them with different 
NOXA
BAD
BCL2
BCLxl
BCLw
MCL1
A1
BIM
BID
PUMA
BMF
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affinities to at least three intracellular membranes: the outer mitochondrial 
membrane, the endoplasmic reticulum (ER) and the nuclear envelope.  
Pro-apoptotic members of the BAX/BAK like subgroup (BAX, BAK, BOK, BCLxs) 
possess two or three BH domains and a TM-domain while BH3-only proteins (BIK, 
BAD, BID, BIM, NOXA, PUMA, BMF) share only the BH3 domain (Fig. 1.6). Both 
subgroups of pro-apoptotic Bcl2 protein family members are essential for the 
induction of apoptosis (Cory and Adams, 2002; Coultas and Strasser, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 | Protein structure of the Bcl2 protein family. The Bcl2 protein 
family consists of anti- (A) and pro-apoptotic members (B) that share at least 
one conserved Bcl2 homology domain (BH domain).  
The anti-apoptotic members (BCL2, BCLxl, BCLw, A1, MCL1) possess four BH 
domains and an amino-terminal (N-terminal) transmembrane (TM) domain.  
The pro-apoptotic members can be subdivided in the multidomain proteins and 
the BH3-only proteins. The multidomain proteins (BAX, BAK, BOK) possess 3 
BH domains and an N-terminal TM-domain, while the BH3-only proteins (BID, 
BIM, BIK, BMF, BNIP3, HRK, NOXA, PUMA) comprise only a single BH3 
domain. 
1.3.1 Regulation of apoptosis by the Bcl2 protein family 
To date, there are two proposed models that explain how the Bcl2 protein family 
regulates MOMP: (i) the indirect activator model and (ii) the direct activator-
derepressor model. Both models result in the activation of BAX and BAK and the 
permeabilization of the outer mitochondrial membrane.  
BH4 BH3 BH2 BH1 TM
BH3
BH3 BH2 BH1 TM
A: Anti-apoptotic Bcl2 proteins: 
B: Pro-apoptotic Bcl2 proteins:
Multidomain proteins
BH3-only proteins
A1, BCL2, BCLxl, BCLw, MCL1
BAX, BAK, BOK
BID, BIM, BIK, BMF, BNIP3, 
HRK, NOXA, PUMA
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The indirect activator model postulates that BAX and BAK are bound in a 
constitutively active state to anti-apoptotic Bcl2 proteins. Competitive interactions 
with pro-apoptotic BH3-only proteins and anti-apoptotic Bcl2 proteins are sufficient to 
release active BAX and BAK and induce MOMP (Fig. 1.7). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 | Regulation of MOMP by the Bcl2 protein family. A, The indirect 
activator model postulates that BAX and BAK are bound in a constitutively 
active state to anti-apoptotic Bcl2 proteins. Competitive interactions with pro-
apoptotic BH3-only proteins and anti-apoptotic Bcl2 proteins are sufficient to 
release active BAX and BAK and induce MOMP. B, The direct-activator-
derepressor or neutralization model implies that BAX and BAK are activated 
after binding to a subset of BH3-only proteins, referred to as direct activators. 
Anti-apoptotic Bcl2-proteins prevent MOMP either by sequestering activated 
BAX and BAK or by inhibiting the direct activator BH3-only proteins. A second 
subset of BH3-only proteins cannot directly activate BAX or BAK but neutralize 
anti-apoptotic Bcl2 proteins. In the indirect activator model BAX and BAK are 
thought to be in a constitutively active state, and bound and thereby inhibited by 
anti-apoptotic Bcl2 proteins. In this model the competitive interaction of BH3-
only proteins with anti-apoptotic Bcl2 proteins is sufficient to release of BAX and 
BAK and initiate MOMP.  
In the direct activator-derepressor model (also called neutralization model), BAX and 
BAK are activated by the interaction with a subset of BH3-only proteins, such as BID 
and BIM, called direct activators. In this model, anti-apoptotic Bcl2 proteins either 
inhibit MOMP by antagonizing BAX or BAK directly or by sequestering the direct 
activator BH3-only proteins thus preventing them to activate BAX or BAK. A second 
subset of BH3-only proteins, called sensitizer, such as NOXA or BAD, cannot directly 
pro-apoptotic
BH3-only
proteins
BAX or BAK
anti-apoptotic
Bcl2
proteins
active
pro-apoptotic
BH3-only
proteins
pro-apoptotic
BH3-only
proteins
BAX or BAK
anti-apoptotic
Bcl2
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A: indirect activator model B: direct activator-derepressor model
sensitizer direct activator
activation
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activate BAX or BAK but antagonize anti-apoptotic Bcl2 proteins and thereby release 
BAX and BAK for the activation by direct activator BH3-only proteins (Fig. 1.7). 
Definitive proof for either model has been difficult to obtain, it is likely that certain 
aspects of both models are correct (Tait and Green, 2010). 
1.4 p53-mediated apoptosis in response to DNA damage  
In response to DNA damage, cells activate a highly conserved signalling network to 
arrest the cell cycle and initiate DNA repair. If the extent of damage is beyond repair 
capacity, additional pathways leading to the induction of apoptosis are activated to 
eliminate these potentially cancerous cells (Levine, 1997). The decision whether cell 
survival is sustained or the DNA damage induced apoptotic pathway (DDIA) is 
initiated depends on the nature of the DNA damage and the physiologic status of the 
damaged cell. For instance, thymocytes are highly primed to undergo DDIA. By 
contrast, primary fibroblasts appear to resist DDIA (Norbury and Zhivotovsky, 2004).  
In germ cells, mechanisms for limiting genome alterations are required for faithful 
propagation of the species, whereas in somatic cells, responses to DNA damage 
prevent the accumulation of mutations that might lead to altered cell proliferation. Not 
surprisingly, several genes that regulate cellular responses to DNA damage function 
as tumour suppressors and defects in the DDIA contribute to tumourigenesis.  
Central in the DDIA is the ATM (ataxia telangiectasia mutated) family of PI3 kinases 
such as ATM and ATR (Wang, 1998) responding to double strand breaks and single-
stranded lesions (Shiloh, 2003). ATM and ATR are responsible for the post-
translational stabilization and thus accumulation of p53 (Oren, 1999). ATM directly 
phosphorylates p53 at serine 15 and indirectly at serine 20 residues through the 
induction of the CHK2 kinase (Banin et al., 1998). Phosphorylation of p53 is believed 
to be critical for the stabilization and activation of p53. Activated p53 translocates to 
the nucleus where it induces the transcription of several pro-apoptotic molecules, 
including BAX and the BH3-only proteins PUMA and NOXA (Miyashita and Reed, 
1995; Nakano and Vousden, 2001; Oda et al., 2000) which in turn initiate MOMP and 
apoptosis (Fig. 1.8). Interestingly, p53 is required for DDIA in certain but not all cell 
types (Clarke et al., 1993; Lowe and Gold, 1993; Strasser et al., 1994).  
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Figure 1.8 | DNA damage-induced apoptosis. Upon DNA damage ATM and 
ATR kinases get activated. ATM phosphorylates and thereby stabilizes p53 
directly at serine 15 and indirectly at serine 20 by the induction of CHK2. 
Activated p53 induces the transcription of BAX, PUMA and NOXA, ultimately 
resulting in MOMP. Activated CHK2 can also induce apoptosis by less 
investigated p53-independend signalling pathways. Besides apoptosis, 
ATM/ATR also induce signalling pathways resulting in cell-cycle arrest and DNA 
repair. 
Common anti-cancer chemotherapeutics frequently engage the DDIA and thus 
defects in this critical regulatory mechanism promote resistance of cancer cells to a 
variety of therapeutic agents. Since de novo protein synthesis is supposed to be 
essential in mediating DDIA, it is widely believed that deregulation of transcription 
represents the main factor giving rise to chemoresistance. For instance, loss of p53 
function is described in over 50% of human cancers, resulting in the inability of p53-
mediated transcriptional up-regulation of pro-apoptotic molecules (Hollstein et al., 
1994). However, disturbed post-transcriptional regulatory mechanisms, such as 
degradation of components of the DDIA pathway are now beginning to be recognized 
as a potential mediators of chemoresistance.  
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1.5 The Ubiquitin-Proteasome System  
The Ubiquitin-Proteasome System (UPS) is the main driver of regulated protein 
degradation in all eukaryotic cells (Ciechanover et al., 1984). Defects in UPS 
pathway have been implicated in a number of human pathologies, most notably in 
cancer and neurodegenerative diseases. In addition to the regulation of critical 
cellular pathways, including cell growth and proliferation, protein quality control, DNA 
repair, transcription, and immune response the UPS plays a critical role in regulating 
cell death (Eldridge and O'Brien, 2010). On the one hand the UPS is responsible for 
the direct degradation of several proteins involved in the regulation of apoptosis, on 
the other hand the UPS impacts on the transcription of several pro- and anti-
apoptotic proteins through the degradation of their transcriptions factors such as p53 
(Bernassola et al., 2010).  
Degradation of a protein by the UPS involves two distinct and successive steps: (i) 
covalent attachment of multiple ubiquitin molecules to the target protein, and (ii) 
degradation of the tagged protein by the 26S proteasome. 
Proteins are targeted for proteasomal degradation by the covalent attachment of 
multiple ubiquitin molecules (Ub). The Ub conjugating system operates in a three-
step mechanism, with three distinct enzymes catalyzing each step. First, a Ub gets 
activated in its amino-terminal glycine by the Ub-activating enzyme (E1). Next, the 
activated Ub is transferred by one of several dozens of Ub-conjugating enzymes (E2) 
to one of several hundreds of substrate specific Ub-ligases (E3s) that finally attaches 
the Ub to the target protein (Pickart, 2001; Wilkinson, 1999). Finally, there are nearly 
100 deubiquitylating enzymes (DUBs) that counter the activity of E3 ligases in 
regulatory pathways, as well as functioning in ubiquitin maturation and ubiquitin 
cleavage and -recycling at the 26S proteasome (Fig. 1.9) (Nijman et al., 2005). 
The first Ub is either transferred to a ε-NH2 group of a lysine residue (K) of the target 
protein to generate an isopeptide bond, or in a linear manner to the N-terminal 
residue of the substrate. Subsequent Ub addition can occur through isopeptide 
linkage on all of ubiquitin’s seven lysine residues as well as its N-terminal primary 
amine, thereby generating a diverse range of chain topologies that can drive a variety 
of different protein fates (Breitschopf et al., 1998; Peng et al., 2003). K48-linked 
polyubiquitin chains serve as a specific tag for protein degradation by the 26S 
proteasome, while other polyubiquitin chains such as K63 chains are involved in 
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other signalling processes such as NFkB-activation and DNA repair (Chen, 2005; 
Sun and Chen, 2004; Voges et al., 1999).   
 
 
 
 
Figure 1.9 | The Ubiquitin Proteasome System. Ubiquitin is activated and 
conjugated to target proteins by a conserved series of E1 (ubiquitin-activating 
enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase) activities. 
In some cases, an isopeptidase or a deubiquitylating enzyme (DUB) may 
oppose the activity of the E3. Polyubiquitylated proteins are recruited (via 
ubiquitin receptors) to the 26S proteasome, a multisubunit, barrel-shaped 
cellular protease consisting of a 20S core particle bound at one or both ends by 
19S cap particles. This 19S cap confers both ATP- and ubiquitin-dependency to 
proteolysis by the 26S proteasome, and contains isopeptidase activities that 
remove ubiquitin from the substrate for recycling and ATPase activities that 
unfold the substrate and feed it into the 20S core for degradation (Eldridge and 
O'Brien, 2010). 
The 26S proteasome is a multisubunit protease complex, which in eukaryotic cells 
shows both nuclear and cytosolic localization. It is comprised of the 20S proteasome, 
which serves as the catalytic core, as well as two regulatory 19S subunits (cap) at 
either end. The regulatory 19S cap is composed of an 11-protein lid and a 10-protein 
base. The lid is responsible for recognition of polyubiquitylated substrates and 
detachment of the poly-Ub-chain. The base is essential for substrate-unfolding and 
entry of the substrate into the 20S core. The 20S core is responsible for proteolysis 
of the substrates (Voges et al., 1999). It compromises three different catalytic 
subunits (β1, β2, β5), each with a different proteolytic specificity: the trypsin-like-
activity (β1), caspase-like-activity (β2) and chymotrypsin-like-activity (β5) (Fig. 1.10). 
In all three β-subunits, a threonin-residue in the catalytic centre is essential for 
Eldridge and O´Brien, 2010 
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catalysis, with the γ-hydroxy-group serving as nucleophil and the α-amino-group 
serving as proton-donor/acceptor during hydrolysis (Dick et al., 1998; Nussbaum et 
al., 1998).  
 
Figure 1.10 | Structure of the 26S proteasome. The 26S proteasome is 
comprised of two 19S regulatory subunits and a 20S core unit.  
The 19S complex consists of two sub-complexes: (i) the base (purple), which 
includes six AAA-ATPases and two non-ATPase proteins, is responsible for 
protein-unfolding and entry into the 20S core; and (ii) the lid (orange) consisting 
of 9 non-ATPase proteins, which is responsible for poly-Ub-recognition and 
detachement.  
The 20S catalytic core complex is assembled of 28 subunits (14 different) 
building the outer α-subunits (green) and the inner β-subunit (blue). The β-
subunit includes the catalytic centres β1, β2, β5 (red) responsible for caspase-
like, trypsin-like and chymotrypsin-like activity, respectively.   
1.5.1 Inhibition of the UPS as a therapeutic approach 
Given the important role of the UPS in maintaining protein homeostasis and in 
regulating cellular processes such as apoptosis, the inhibition of components of the 
UPS has been seen as a promising target in the development of new therapeutics in 
the anti-cancer treatment. In 1994 inhibitors of the proteasome have first been 
described to induce apoptosis (Rock, Gramm et al. 1994), probably by changing the 
expression level of pro- and anti-apoptotic proteins, for instance pro-apoptotic 
members of the Bcl2 protein family. Accordingly, several pro-apoptotic members, 
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such as BAX, BIK, BIM and NOXA have been reported to accumulate upon 
proteasome inhibition. While BAX and BIK are thought to accumulate due to a block 
in their proteasomal degradation (Liu et al., 2008; Zhu et al., 2005), NOXA and BIM 
accumulation is reported to occur at the transcriptional level as a result of 
stabilization of their transcription factors, such as p53 (Fernandez et al., 2005; Perez-
Galan et al., 2006).  
The proteasome inhibitor bortezomib (PS-341, Velcade) (Adams, 2002) was the first 
drug that targets a component of the UPS and was first approved for clinical use in 
the United States (Chauhan, Hideshima et al. 2005). Bortezomib functions as a 
reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome with a Ki of 
0.6 nM. It binds the catalytic threonine in the active site of the β5 subunit, which also 
results in a reduction of the catalytic activities of the caspase-like and trypsin-like 
subunits. Developed by ProScript Inc in 1995, Bortezomib entered clinical trials in 
1997 and was approved by the Federal Drug Administration (FDA) in 2003. 
Bortezomib-treatment results in clinical benefit in the treatment of haematological 
malignancies, such as multiple myeloma or mantle cell lymphoma. Bortezomib is 
currently undergoing Phase III clinical trials for follicular non-Hodgkin’s lymphoma, in 
Phase II trials for diffuse large B cell lymphoma, and a great many other clinical trials 
(Yang et al., 2009). Interestingly, bortezomib-induced apoptosis preferentially occurs 
in malignant but not in non-malignant cells of some tumour tissues, although the 
detailed mechanism is still under investigation (Fernandez et al., 2005; Qin et al., 
2005). 
Besides the clinical benefit, substantial side-effects and resistance have been 
observed following bortezomib-treatment. Furthermore, the effect of bortezomib in 
the treatment of solid tumours has been less promising. Nevertheless, the surprising 
efficacy (and rapid clinical approval) of bortezomib for the treatment of multiple 
myeloma and mantle cell lymphoma has encouraged researchers to explore the 
possibility of targeting other components of the UPS in order to introduce more 
specific anti-cancer therapies. 
1.6 Aim of the work 
Numerous reports show that compounds inhibiting proteasomal activity are able to 
selectively induce tumour cell apoptosis (Rock, Gramm et al. 1994). However the 
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underlying mechanisms giving rise to the selective cytotoxicity of tumour cells toward 
proteasome inhibitors are incompletely understood. Bortezomib, a pharmacological 
inhibitor of the proteasome, is already successfully used in the clinical treatment of 
several types of cancer. However, besides beneficial effects substantial side-effects 
and resistance have been reported (Yang et al., 2009). Nevertheless, the initial 
beneficial effects clearly highlight the promising role of the UPS as a valuable 
therapeutic target in the treatment of cancer. 
The current work aims to understand the detailed mechanisms of bortezomib-
induced apoptosis. Moreover, the knowledge of why tumour cells are more 
susceptible to proteasome inhibitors may contribute to understand the 
pathophysiology of malignant transformation and may facilitate efforts aiming to 
design a novel anti-cancer therapy. 
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2 Material and methods 
2.1 Chemicals 
Unless indicated otherwise, all chemicals were from Roth (Karlsruhe, Germany) or 
Sigma (Deisenhofen, Germany).  
Trichostatin A, 5-Aza-2´Deoxycytidine, etoposide, doxorubicin, and LDN-57444 were 
from Sigma (Deisenhofen, Germany) and bortezomib from Teva (Berlin, Germany). 
2.2 DNA constructs 
For construction of GFP-fusion proteins, open reading frames (ORF) encoding 
human NOXA-wt, NOXA-K0 or UCH-L1, were amplified by PCR and cloned into 
pEGFP-C3 vector (Clontech, Takara Bio Europe, Saint-German-en-Laye, France). 
GFP-UCH-L1D176N was obtained by site directed mutagenesis PCR using GFP-UCH-
L1 as template and UCH-L1-mut primer. 
For the construction of myc-fusion proteins ORF encoding human NOXA-wt or 
NOXA-K0 were amplified by PCR and cloned into pCDNA3.1+ vector (Invitrogen, 
Karlsruhe, Germany) already containing an amino-terminal myc-sequence. 
For the construction of HA-fusion proteins ORF encoding human NOXA-wt or NOXA-
K0 were amplified by PCR with primers encoding an amino-terminal HA-sequence 
and cloned into pCDNA3.1+ vector. 
NOXA-wt and NOXA-K0 cDNA were obtained from Addgene (Cambridge, USA). 
Myc-UCH-L1 cDNA was a kind gift from Prof. K.J. Lee (Ewha Womans University, 
Seoul, Korea).  
Myc-XIAP has been described previously (Kashkar et al., 2007). 
All PCR amplifications have been performed with appropriate primers containing 
specific restriction sequences using Phusion™ High Fidelity DNA Polymerase. After 
restriction with the appropriate enzyme PCR-Fragments and vectors have been 
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separated by argarose gel electrophoresis (Agarose from Peqlab, Erlangen, 
Germany) in TE buffer (10 mM Tris-Cl, pH 7.5. 1 mM EDTA) using 
ethidiumbromide for nucleic acid staining, cleaned up with NucleoSpin® Gel and PCR 
Clean-up Kit and ligated using the Rapid DNA Ligation Kit according to the 
instructions of the manufacturer with a molecular template:vector ratio of 3:1. 
Plasmid-DNA has been propagated in E.coli XL1-blue and preparated using 
NucleoSpinPlasmid (Mini) or NucleoBondPlasmid (Maxi) according to the instructions 
of the manufacturer. All constructs used in this work have been sequenced by GATC 
(Tübingen, Germany). 
 
Table 2.1 | Kits and enzymes used for the construction of DNA constructs 
Name Company 
Phusion™ High Fidelity DNA 
Polymerase  
Finnzymes, Fisher Scientific GmbH, 
Schwerte, Germany 
Rapid DNA Ligation Kit Fermentas, Leon-Roth, Deutschland 
Restriction enzymes Fermentas, Leon-Roth, Deutschland 
NucleoSpinPlasmid (Mini) 
NucleoBondPlasmid (Maxi) 
MACHEREY-NAGEL GmbH & Co. KG, 
Düren, Germany 
NucleoSpin® Gel and PCR Clean-up 
 
MACHEREY-NAGEL GmbH & Co. KG, 
Düren, Germany 
 
Table 2.2 | DNA constructs used in this work with specific primers 
Construct in 
pEGFP-C3 
MW 
(kDa) 
aa 
(bp) 
5’ primer with 
restriction side 
3’ primer with 
restriction side 
GFP-NOXA-wt 35,9 915 5' EcoR1-NOXA 3' BamH1-NOXA 
GFP-NOXA-K0 35,9 915 5' EcoR1-NOXA 3' BamH1-NOXA 
GFP-UCH-L1 52,7 1413 5' HindIII-UCH-L1 3' BamH1-UCH-L1 
GFP-UCH-L1D176N 52,7 1413 5' UCH-L1-mut 3' UCH-L1-mut 
 
Construct in 
pCDNA3.1+ 
MW 
(kDa) 
aa 
(bp) 
5’ primer with 
restriction side 
3’ primer with 
restriction side 
HA-NOXA-wt 7,8 192 5' HindIII-HA-NOXA-wt 3' XhoI-NOXA 
HA-NOXA-K0 7,8 192 5' HindIII-HA-NOXA-K0 3' XhoI-NOXA 
Myc-NOXA-wt 8,2 210 5' BamH1-NOXA 3' XhoI-NOXA 
Myc-NOXA-K0 8,2 210 5' BamH1-NOXA 3' XhoI-NOXA 
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Table 2.3 | Primer used for the generation of DNA constructs used in this work 
Primer name Sequence (5'-3') 
5' BamH1-NOXA CCC CCC CCC GGA TCC ATG CCT GGG AAG AAG 
GCG CG 
3' XhoI-NOXA CCC CCC CCC TCG AGT CAG GTT CCT GAG CAG 
AAG 
5' EcoR1-NOXA CCC CCC CCG AAT TCT GAT GCC TGG GAA GAA 
GGC GCG 
3' BamH1-NOXA CCC CCC CCG GAT CCT CAG GTT CCT GAG CAG 
AAG 
5' HindIII-UCH-L1 GAT CAA GCT TAT GCA GCT CAA GCC GAT GGA G 
3' BamH1-UCH-L1 GAT CGG ATC CTT AGG CTG CCT TGC AGA GAG C 
5' HindIII-HA-NOXA-wt GAT CAA GCT TAC ATG TAC CCA TAC GAT GTT CCA 
GAT TAC ATG CCT GGG AAG AAG GCG CGC 
5' HindIII-HA-NOXA-K0 GAT CAA GCT TAC ATG TAC CCA TAC GAT GTT CCA 
GAT TAC ATG CCT GGG AGA AGA GCG CGC 
5' UCH-L1-mut GGC CAC CTC TAT GAA CTT AAT GGA CGA ATG CCT 
TTT C 
3' UCH-L1-mut ATC CAC GTT GTT AAA CAG AAT AAA ATG G 
2.3 Cell culture and transfection 
All cell culture media and additives were from Biochrom (Berlin, Germany). Plastic 
material was obtained from TPP (Trasadingen, Switzerland), Nunc (Roskilde, 
Denmark) or BD Biosciences (Falcon™, Franklin Lakes, USA). 
The establishment and maintenance of the following cells and cell lines has been 
described previously: L428, L591, L1309 (Kashkar et al., 2007), MeWo (Seeger et 
al., 2010), SKmel23, SKmel28, MV3, WM164 (Zigrino et al., 2005), Colo38 
(Giacomini et al., 1986), and primary melanoma cells derived from Pat1 (HOM1), 
Pat2 (HM1), Pat3 (MOO1) (Schmidt et al., 2011). HEK293FT, HeLa, DLD1, HT29 
and LS174T were from ATCC (CRL-11268, Rockville, MD, USA) and maintained 
according to the instructions of the manufacturer.  
In brief, cells were expanded to an adequate amount and several aliquotes were 
frozen by -150°C in FCS containing 10% DMSO. Experiments were performed after 
resawing and expanding of cells to 4 passages. Cells were cultured at 37°C in the 
following media: 
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Table 2.4 | Cell culture media used in this work 
Name Media Additives 
L428, L591, L1309, 
LS174T, DLD1 
VLE-RPMI 10% FCS 
1% penicillin/streptomycine 
MeWo, SKmel23, MV3,  
WM164, SKmel28, Colo38  
Pat1 (HOM1), Pat2 (HM1)  
Pat3 (MOO1) 
VLE-RPMI 10% FCS 
1% penicillin/streptomycine 
1% non-essential aa 
HEK293FT DMEM 10% FCS 
1% penicillin/streptomycine 
1% non-essential aa 
2 mM L-glutamine  
10 mM sodium pyruvate 
2400 U/ml G418 
HeLa, HT29 DMEM 10% FCS 
1% penicillin/streptomycine 
 
Primary melanoma cells and HeLa cells were transfected using LipofectamineTM LTX 
(Invitrogen, Karlsruhe, Germany). HEK293FT cells were transfected using the 
standard calcium phosphate method (Wiegler et. al, 1978).  
For siRNA mediated knock-down Pat1 cells were transfected with 100 pmol/µl siRNA 
using LipofectamineTM LTX (Invitrogen, Karlsruhe, Germany). 
 
Table 2.5 | siRNAs used in this work 
Name Sequence Company 
siUCH-L1 sense: 
AAGUUAGUCCUAAAGUGUAtt 
antisense: 
UACACUUUAGGACUAACUUct 
Ambion, Applied 
Biosystems  
Alexa Fluor-594-labelled 
scr-control RNA 
All star non targeting mix Invitrogen, Karlsruhe, 
Germany 
2.4 Cytotoxic treatments and cell viability 
Cells (105 per well) were incubated in 96-well plastic plates at 37°C in full media and 
treated with increasing concentrations of etoposide, doxorubicin, 5-Aza-2´Deoxy-
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cytidine, Trichostatin A, LDN-57444 or bortezomib and incubated for the indicated 
time periods.  
Cell viability was assessed by XTT test (XTT cell viability kit, Roche Applied 
Sciences, Mannheim, Germany) according to the instructions of the manufacturer. 
Briefly, after treatments cells were incubated with the XTT reagents at 37°C for 4 
hours. The absorbance of the samples was measured with an enzyme-linked 
immunosorbent assay (ELISA) reader (HT III, Anthos Lab Tech Instruments, 
Salzburg, Austria) by wavelength 450 nm and reference wavelength 620 nm. The 
data are mean values of 3 different experiments in triplicate. Values of absorbance of 
untreated cells (after background subtraction) were set as 100 % viability.  
Cell death was measured by trypan blue exclusion using an automated cell counter 
(CountessTM, Invitrogen, Karlsruhe, Germany).  
2.5 qPCR 
Total RNA was isolated from indicated cells using the standard phenol-chloroform-
method (Chomczynski and Sacchi, 1987).  
cDNA was synthesised using RevertAidTMPremium First Strand cDNA Synthesis Kit 
(Fermentas, Leon-Roth, Deutschland) using polyT-primers according to the 
manufacturer´s instructions. qPCR was performed with specific primers for NOXA (fw 
GCT CCA GCA GAG CTG GAA GT; rev CCA TCT TCC GTT TCC AAG GGC) and 
GAPDH as a reference (fw GGT ATC GTG GAA GGA CT; rev GGG TGT CGC TGT 
TGA A) using LightCycler® SYBR-Green I Mix (Roche Applied Sciences, Mannheim, 
Germany) with a 96well-plate Multicolor Real-Time PCR Detection System  (iQTM5, 
BIO-RAD, Herkules, USA) and data were further evaluated using the Pfaffl-method 
(Pfaffl, 2001).  
2.6 Sample preparation and immunoblotting (IB) 
Whole cell extracts were prepared by incubating cell pellets in CHAPS lysis buffer on 
ice for 20 minutes. Samples were centrifuged, and supernatants were recovered. 
Poly (ADP-ribose) polymerase (PARP) cleavage was assessed after incubation of 
cell pellets in urea extraction buffer following denaturation at 100°C for 10 minutes.  
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Protein concentration was determined using BCA Assay Protein Quantification 
(Pierce, Bonn, Germany) according to the instructions of the manufacturer. 
Equal amounts of protein were separated by sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis (SDS-PAGE) using the Miniprotean3 PAGE and Western Blotting 
Apparatus (BIO-RAD laboratories, Herkules, USA). 
Samples were heated in SDS sample buffer for 5 minutes at 100°C and centrifuged 2 
minutes at 20,000 x g. Polyacrylamid gels (10 – 14%) were started at 120 mV and 
continued at 180 mV in SDS running buffer. After blotting gels on nitrocellulose 
membranes (Protan, Schleicher & Schuell, GE healthcare, Freiburg, Germany) for 90 
minutes in blot transfer buffer, membranes were blocked for 30 minutes in blocking 
buffer and incubated with primary antibody, diluted in antibody dilution buffer for one 
hour. After washing and incubation with secondary antibody for one hour, signals 
were detected on film (Amersham Inc., GE healthcare, Freiburg, Germany) using 
enhanced chemiluminescence (ECL Western Blotting Substrate, Pierce, Bonn, 
Germany). 
 
Table 2.6 | Antibodies used for IB 
Anti-β-Actin  Mouse-IgG, monoclonal Sigma Deisenhofen, 
Germany 
Anti-BIM Rabbit-IgG, monoclonal Cell Signaling, Boston, USA 
Anti-Caspase-9 Rabbit-IgG, monoclonal Cell Signaling, Boston, USA 
Anti-GFP Mouse-IgG, monoclonal Roche Diagnostics GmbH, 
Mannheim, Germany 
Anti-MYC Mouse-IgG, monoclonal Invitrogen, Karlsruhe, 
Germany 
Anti-NOXA Mouse-IgG, monoclonal Calbiochem, USA 
Anti-PARP Mouse-IgG, monoclonal BD PharMingen, USA 
Anti-PUMA Rabbit-IgG, monoclonal Cell Siganling, Boston, USA 
Anti-Ubiqutin-K48-specific 
(Apu2) 
Rabbit-IgG, monoclonal Millipore, Schwalbach, 
Germany 
Anti-UCH-L1 Rabbit-IgG, monoclonal Cell Signaling, Boston, USA 
Anti-UCH-L3 Rabbit-IgG, monoclonal Cell Signaling, Boston, USA 
Anti-XIAP Mouse-IgG, monoclonal BD Transduction 
Laboratories, USA 
Anti-Rabbit IgG HRP-linked Goat Sigma, Deisenhofen, 
Germany 
Anti-Mouse IgG HRP-linked Goat Sigma, Deisenhofen, 
Germany 
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Table 2.7 | Buffers used for sample preparation and IB 
Antibody dilution buffer 50 mM Tris, pH 7.6 
150 mM NaCl 
0.1% Tween-20   
5% BSA  
Blocking buffer 10 mM Tris-HCl, pH 7.4-7.6 
150 mM NaCl 
5% milk powder 
2% BSA 
0.1% Tween-20 
Blot transfer buffer 25 mM Tris-HCl 
190 mM glycine 
20% methanol 
CHAPS lysis buffer 10 mM HEPES, pH 7.4 
150 mM NaCl  
1% CHAPS  
complete protease inhibitor cocktail  
SDS sample buffer (5x) 25% glycerol 
0.6 M Tris-HCl 
144 mM SDS 
0.1% brome phenol blue 
SDS running buffer 190 mM glycine 
20 mM Tris 
0.1% SDS 
S-PBS 120 mM NaCl 
10 mM NaH2PO4 
30 mM K2HPO4 
pH 7.6 
Urea extraction buffer 50 mM Tris, pH 6.8  
6 M urea  
3% SDS  
10% glycerol  
0.00125% bromophenol blue  
5% 2-mercaptoethanol 
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2.7 Immunoprecipitations (IP) 
For the detection of ubiquitylated tagged-NOXA in HEK293FT cells, cells were 
transfected with indicated plasmids. 24 hours after transfection HEK293FT cells were 
denaturated prior Immunoprecipitation (IP). Cells were lysed in 100 µl IP-lysis buffer 
containing 1% SDS and boiled for 30 minutes. The lysate was diluted with 900 µl IP-
lysis buffer to obtain a final SDS concentration of 0.1% and HA- or myc-tagged 
protein IP was performed by magnetic epitope labelling using HA- or myc-tag µMACS 
Epitope Tag Protein Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) 
according to the instructions of the manufacturer. Due to restricted material 
transfected Pat1-2 cells were directly lysed in IP-lysis buffer 24 hours after 
transfection and tag-specific IP was performed without prior denaturation. After 
binding columns were washed 6 x with washing buffer 1 and 1x with washing buffer 
2. IPs were eluted with elution buffer and further analysed by IB.  
For binding assays HEK293FT cells were transfected with indicated plasmids. 24 
hours after transfection cells were lysed in IP-lysis buffer and GFP-tagged protein IP 
was performed by magnetic epitope labelling using GFP-tag µMACS Epitope Tag 
Protein Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the 
instructions of the manufacturer. After binding columns were washed 3x with IP-lysis 
buffer, eluted with elution buffer and further analysed by IB. 
 
Table 2.8 | Buffers used for IP 
IP-lysis buffer 150 mM NaCl  
1% Triton X-100  
50 mM Tris HCl, pH 8.0 
Washing buffer 1 150 mM NaCl  
1% NP-40  
0.5% sodium deoxycholate  
0.1% SDS,  
50 mM Tris-HCl, pH 8.0 
Washing buffer 2 20 mM Tris-HCl, pH 7.5 
Elution buffer  50 mM Tris-HCl  
50 mM DTT  
1% SDS  
0.005% bromophenol blue  
10% glycerol, pH 6.8 
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2.8 In vitro deubiquitylation and binding assays 
HEK293FT cells were transfected with HA-NOXA or myc-NOXA and treated for 24 
hours with 100 nM Bortezomib 8 hours post-transfection. Cells were washed twice 
with PBS and mechanically pulped in deubiquitylation assay-buffer (50 mM 
HEPES/NaOH, pH 7.8, 0.5 mM EDTA, 1 mM DTT, 0.1 mg/ml ovalbumin). Equal 
amounts were incubated with recombinant UCH-L1-GST or UCH-L3-HIS (ENZO 
lifescience, Lörrach, Germany) at 25°C. The lysate was diluted 1:10 with IP-lysis 
buffer to reduce the DTT concentration to 0.1 mM prior IP. 
2.9 Fluorescence microscopy 
Cells grown on coverslips were transfected with indicated plasmids. 24 hours after 
transfection cells were washed twice with cold PBS. Cells were then fixed with 3% 
paraformaldehyde in PBS for 20 minutes and blocked with 3% bovine serum albumin 
(BSA) in PBS (blocking buffer) for 30 minutes. Cells were permeabilised with 0.1% 
saponin during blocking, and incubated with the appropriate primary antibody in 
blocking buffer over night at 4°C. Cells were washed twice for 5 minutes with 
blocking buffer and incubated with secondary antibody for 1 hour at room 
temperature. Cells were washed twice with blocking buffer for 5 minutes and once 
with PBS for 5 minutes. Dapi (Molecular Probes, Invitrogen, Karlsruhe, Germany) 
was added into the first washing step (1:5000) for nuclei staining. 
Cells were mounted on glass slides and examined using an Olympus IX81 
fluorescence microscope (Objective: 60x PLAPO oil, NA 1.4) or a Leica DMIRE2 
confocal microscope. If appropriate, images were processed using CellP 
deconvolution software (Olympus SIS).  
 
Table 2.9 | Antibodies used for fluorescence microscopy 
Anti-NOXA Mouse-IgG, monoclonal Calbiochem, USA 
Alexa Fluor 568 anti-mouse Goat Molecular Probes, 
Invitrogen, Karlsruhe, 
Germany 
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2.10 Flow cytometry (FACS) 
For the analyses of NOXA protein stability Pat1-2 cells were transfected with GFP-
NOXA and pDsRed-Express-N1 vector (Clontech, Takara Bio Europe, Saint-
German-en-Laye, France). Cells were fixed with 3% Paraformaldehyde in PBS and 
analysed by flow cytometry (BD FACSCalibur™, BD Biosciences, Heidelberg, 
Germany) and further evaluated with the FlowJo software (Ashland, USA). Relative 
GFP-NOXA or dsRed expression of transfected cells was assed using FITC-median 
or PE-median, respectively. Values represent fold induction of NOXA-expression to 
control sample while each sample was normalized to fold induction of dsRed 
expression to account possible differences in transfection efficiency. 
For the detection of endogenous NOXA cells Pat2 cells were transfected with GFP-
UCH-L1, GFP-UCH-L1D176N or GFP-control vector. 24 hours after transfection cells 
were washed twice with cold PBS. Cells were then fixed with 3% 
paraformaldehyde/PBS for 20 minutes and blocked with 3% bovine serum albumin 
(BSA) in PBS (blocking buffer) for 30 minutes. Cells were permeabilised with 0.1% 
saponin during blocking, and incubated with the appropriate primary anti-NOXA 
antibody in blocking buffer over night. Cells were washed twice with blocking buffer 
and incubated with secondary Alexa Fluor 568 goat anti-mouse antibody for one 
hour. Cells were washed twice with PBS. NOXA expression was assed using PE-
Median in GFP-positive cells and further evaluated with the FlowJo software. Values 
represent fold induction of NOXA-expression relative to GFP-control samples.  
 
Table 2.10 | Antibodies used for flow cytometry 
Anti-NOXA Mouse-IgG, monoclonal Calbiochem, USA 
Alexa Fluor 568 anti-mouse Goat Molecular Probes, 
Invitrogen, Karlsruhe, 
Germany 
2.11 Tissue immunohistochemistry (IHC) 
Paraffin embedded tissues, 6 mm sections, were deparaffinised through three 
changes of xylene, incubating 10  minutes in each change. Slides were hydrated to 
water by dipping them 20–30 times in each of two changes of 100% ethanol, two 
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changes of 95% ethanol, one of 80% ethanol, one of 70% ethanol, and two changes 
of distilled water. Slides were placed in a 95°C water bath, covered with 10 mM 
Citrate buffer (pH 6) for 20 minutes. Thereafter slides were cooled for 30  minutes, 
rinsed in distilled water twice and once in TBS for 5  minutes. Tissue specimens were 
stained with the specific antibodies overnight at 4°C in humidified atmosphere. Slides 
were washed three times for 15 minutes in TBS and incubated with HRP-labelled 
anti-rabbit or anti-mouse polymer (Dako Envision®, Dako, Hamburg, Germany) for 1 
hour at room temperature. Slides were washed three times for 15 minutes in TBS 
and bound antibodies were detected with AEC substrate (Dako Envision®, Hamburg, 
Germany). Nuclei were stained with haematoxylin (Thermo Scientific, Fisher 
Scientific GmbH, Schwerte, Germany). Specimens of human stomach were used as 
positive control for both antibodies staining (kindly provided from the local 
Department of Pathology), negative controls were performed by omitting primary 
specific antibodies.  
 
Table 2.11 | Antibodies used for tissue IHC 
Anti-NOXA (36833) Rabbit-IgG, polyclonal Abcam, Cambridge, UK 
Anti-UCH-L1 (1673P) Mouse-IgG, monoclonal Acris, Herford 
Germany 
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3 Results 
3.1 Proteasome inhibition induces mitochondrial apoptosis 
in a cohort of tumour entities 
Previous data demonstrated that proteasome inhibition has a selective anti-tumour 
activity and significant efficacy against a variety of malignancies (Almond and Cohen, 
2002; Fennell et al., 2008; Hoeller and Dikic, 2009; Orlowski and Kuhn, 2008). 
Bortezomib, a pharmacologic inhibitor of the Ubiquitin Proteasome System (UPS), is 
being used successfully in the treatment of malignant diseases where it improves 
clinical outcomes. These beneficial effects clearly highlight the role of the UPS as a 
target for anti-cancer therapy. Therefore, understanding the molecular mechanism of 
proteasome inhibition in promoting tumour cell death may advance our knowledge 
about the pathways governing cellular homeostasis. Furthermore, this knowledge 
may additionally facilitate efforts aiming at the design and introduction of new cancer 
therapeutics.  
Our viability analysis (XTT assay) of primary tumour cells derived from three 
melanoma patients (Seeger et al., 2010) after bortezomib-treatment showed that 
tumour isolates from different individuals display a highly diverse susceptibility to 
proteasome inhibition (Fig. 3.1A). In contrast to tumour cells derived from patient 1 
(Pat1), Pat2 tumour cells were highly susceptible to bortezomib. Bortezomib-
mediated cell death was caused by mitochondrial apoptosis as monitored by 
immunoblot (IB)- analyses of caspase 9 (casp9) activation/processing and PARP 
cleavage (Fig. 3.2A).  
Results 
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Figure 3.1 | Cytotoxic effect of proteasome inhibition in different tumour 
cells. Cell viability assay (XTT) 24 hours after treatment with increasing 
concentrations of bortezomib in cells derived from melanoma patients (Pat1-3) 
(A), melanoma cell lines (MeWo, Skmel28, Skmel23, MV3, WM164, Colo38) 
(B), Hodgkin Lymphoma (L428, L591) and control B-cell lines (L1309) (C) and 
colorectal carcinoma cell lines (DLD1, LS174T, HT29) (D). 
Similar results in cell viability analyses and analyses of the mitochondrial apoptotic 
pathway were obtained when established tumour cell lines derived from melanoma 
(Fig 3.1B, Fig. 3.2B), Hodgkin Lymphoma (HL) (Fig. 3.1C, Fig. 3.2C) or colorectal 
carcinoma (CRC) patients (Fig. 3.1D, Fig. 3.2D) were exposed to bortezomib. These 
analyses consistently identified a cohort of tumour cells proved to be highly 
susceptible to proteasome inhibition.  
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Figure 3.2 | Proteasome inhibition engages the mitochondrial apoptotic 
pathway in bortezomib-sensitive tumours. Tumour cells derived from 
melanoma patients (Pat1-3) (A), a melanoma cell line (Colo38) (B), Hodgkin 
Lymphoma (HL) cell lines (L591, L428) and a control B-cell line (L1309) (C), 
and colorectal carcinoma (CRC) cell lines (LS174T, DLD1, HT29) (D) were 
treated with increasing concentrations of bortezomib for 24 hours. IB-analyses 
of PARP processing were performed on nuclear extracts. IB-analyses of 
caspase-9 (casp9) activation/processing resulting in the p37 and p35 fragments 
were performed on whole cell lysates. Actin served as a loading control. 
The mitochondrial apoptotic pathway is tightly controlled by the Bcl2 protein family 
comprising anti-apoptotic and pro-apoptotic members that are controlled by a third 
class of pro-apoptotic members called BH3-only proteins. Accordingly, therapeutic 
targeting of the crosstalk between BH3-only and Bcl2 proteins represents a 
promising treatment strategy for cancer (Kelly and Strasser, 2011). Indeed, several 
previous reports indicated that proteasome inhibition induces the mitochondrial 
apoptotic pathway predominantly by altering the expression level of Bcl2 protein 
family members (Fennell et al., 2008; Voorhees and Orlowski, 2006). To investigate 
their potential involvement primary cells from melanoma patients (Pat1-3) were 
treated with increasing concentrations of bortezomib for 24 hours. The following IB-
analysis of the expression levels of several BH3-only-proteins identified NOXA to be 
specifically up-regulated after proteasome inhibition. In contrast, the expression level 
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of other BH3-only proteins such as PUMA and BIM remained unchanged (Fig. 3.3A). 
Similar results were obtained in HL B-cells (Fig. 3.3B). 
 
 
Figure 3.3 | Proteasome inhibition results in the accumulation of the pro-
apoptotic BH3-only protein NOXA. IB-analysis of indicated BH3-only proteins 
in whole cell lysates from tumour cells derived from melanoma patients (Pat1-3) 
(A), Hodgkin Lymphoma (HL) cell lines (L591, L428) and a control B-cell line 
(L1309) (B), a melanoma cell line (Colo38) and colorectal carcinoma (CRC) cell 
lines (LS174T, DLD1, HT29) (C).  Actin served as a loading control. 
Remarkably, the susceptibility to bortezomib-induced apoptosis was tightly 
associated with the magnitude of NOXA accumulation in all tested bortezomib-
sensitive tumour cells including primary cells from melanoma patients, melanoma cell 
lines, HL B-cell lines and CRC cell lines (Fig. 3.3 B and C).  
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3.2 NOXA accumulates at the post-transcriptional level 
after proteasome inhibition  
 
Besides the regulation of direct substrates of the UPS, proteasome inhibition has 
been shown to regulate the transcription of several proteins by stabilizing the relevant 
transcription factors including p53 or NFκB. To examine whether NOXA 
accumulation is due to its transcriptional up-regulation, NOXA-mRNA levels were 
analysed by qPCR after proteasome inhibition. As shown in Fig. 3.4 there was no 
significant up-regulation of NOXA mRNA upon proteasome inhibition, although 
NOXA protein was significantly accumulated in bortezomib-sensitive tumour cells 
derived from melanoma patients (A), melanoma cell lines (B), HL B-cell lines (C) and 
CRC cell lines (D). In contrast, NOXA mRNA was strongly up-regulated upon DNA-
damage induced either by the DNA-intercalating agent doxorubicin, or the 
topoisomerase inhibitor etoposide, even though no accumulation of NOXA-protein 
was detectable.  
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Figure 3.4 | NOXA accumulation after proteasome inhibition is post-
transcriptional. Representative IB-analysis and according relative qPCR-
analysis (normalised to GAPDH mRNA) of three independent experiments in 
triplicate.  
NOXA expression was analysed in tumour cells derived from a Melanoma 
patient (Pat2) (A), a melanoma cell line (Colo38) (B), HL B-cell lines (L428, 
L591) (C) and CRC cell lines (LS174T, DLD1) (D) after treatment with 
bortezomib (A, B, D 25 nM; C 10 nM), etoposide (A 50 µM) or doxorubicin (B, 
C, D 0,5 µM) for 24 hours. HeLa cells were transfected with pEGFP-C3 or GFP-
NOXA and treated 24 hours after transfection with 40 nM bortezomib for 4 
hours, as indicated. IB-analyses of GFP-NOXA and GFP expression were 
performed with whole cell lysates. Upper Blot presents long exposure, bottom 
blot presents short exposure (E). 
The non-transcriptional nature of NOXA accumulation after proteasome inhibition 
was confirmed using HeLa cells transiently transfected with plasmid constructs 
encoding GFP-NOXA under the control of the cytomegalovirus (CMV) promoter. As 
shown in IB-analysis, bortezomib-treatment of transiently transfected HeLa cells 
resulted in the accumulation of ectopically expressed GFP-NOXA but not GFP alone 
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(Fig. 3.4E). These data demonstrate that proteasome inhibition induces NOXA 
protein accumulation irrespective of the transcriptional origin.  
Taken together, NOXA protein expression is controlled by a post-transcriptional 
regulatory mechanism, which appears to be deregulated in bortezomib-sensitive 
tumour cells. 
3.3 NOXA protein is less stable in bortezomib-sensitive 
tumour cells 
In order to examine NOXA protein turnover, GFP-NOXA (1, 2, 3, or 4 µg DNA 
constructs ) was ectopically expressed in bortezomib-resistant Pat1 and bortezomib-
sensitive Pat2 tumour cells. Transfection-efficiency among the different patient cells 
was highly variable and the expression levels of GFP-NOXA were normalized to the 
expression levels of co-transfected dsRed (also under the control of the CMV 
promoter) as an internal control. In contrast to dsRed, GFP-NOXA was barely 
detectable in Pat2 tumour cells in IB-analyses even though increasing amounts of 
DNA were transfected. In contrast, Pat1 tumour cells exhibited a high GFP-NOXA 
expression even though little amounts of DNA were transfected (Fig. 3.5A). In order 
to illustrate the statistical significance of these findings, expression levels of NOXA-
GFP were quantified by flow cytometry (FACS). The expression levels of GFP-NOXA 
(FITC-median of GFP-positive cells) were normalized to the expression levels of 
dsRed (PerCP-median of PerCP-positive cells) from the same samples and are 
presented as fold induction to the control sample (1 µg GFP-NOXA). Fig 3.5B shows 
GFP-NOXA expression in Pat1 versus Pat2 cells. A linear increase of GFP-NOXA 
expression upon increasing amounts of transfected DNA in Pat1 cells was observed, 
whereas GFP-NOXA was only weakly expressed in Pat2 cells.  
NOXA protein stability was further examined using cycloheximide (CHX) treatment to 
block protein synthesis 24 hours post-transfection. As described above, GFP-NOXA 
expression was quantified by FACS-analysis using dsRed as an internal control. 
Values are presented as fold induction of GFP-NOXA expression compared to the 
control sample (t=0h). Congruently, GFP-NOXA was found to be markedly unstable 
in Pat2 tumour cells (Fig. 3.5C).   
These data demonstrate the reduced stability of NOXA protein in bortezomib-
sensitive tumour cells.  
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Figure 3.5 | NOXA protein is less stable in bortezomib-sensitive tumours. 
Primary cells from melanoma Pat1-2 where transfected with increasing amounts 
of GFP-NOXA DNA and 1 µg dsRed. GFP-NOXA expression was analysed by 
IB (A) and FACS (B). Cells were transfected with 2 µg (Pat1) or 4 µg (Pat2) of 
GFP-NOXA DNA and 1 µg dsRed and treated with 25 µg/ml Cycloheximide 
(CHX) and GFP-NOXA expression was analysed by FACS (C). 
GFP-NOXA expression was normalized to co-transfected dsRed and then 
normalized to the µg=1 or t=0 (B,C, respectively) controls. Data are presented 
as mean +/- SEM of 3 independent experiments, with statistical significance 
determined by Students t-test.  
3.4 NOXA is increasingly ubiquitylated in bortezomib-
sensitive tumour cells 
The UPS is responsible for the degradation of cellular proteins in eukaryotic 
organisms and represents a fundamental cellular quality control pathway to modulate 
cell fate. Substrates of the UPS are tagged for degradation by the 26S proteasome 
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with a polyubiquitin chain, which is specifically linked at Lysine48 (K48) of each 
ubiquitin molecule. If NOXA is a direct substrate of the UPS, it will be ubiquitylated 
with a K48-linked ubiquitin chain prior to its degradation. To investigate this 
issue, HA-tagged NOXA (HA-NOXA) (Fig. 3.6A) or myc-tagged NOXA (myc-NOXA) 
(Fig. 3.6B) was overexpressed in HEK293 FT cells and K48-linked ubiquitylation of 
NOXA was investigated in tag-specific immunoprecipitates.  
 
 
Figure 3.6 | NOXA ubiquitylation is accelerated in bortezomib-sensitive 
tumour cells. HEK293FT cells were transfected with myc-NOXA-wt and myc-
NOXA-K0 (A) or HA-NOXA-wt and HA-NOXA-K0 (B). 24 hours after 
transfection proteins were denaturated by boiling lysates in 1% SDS. IB-
analyses of K48-linked polyubiquitin (UbK48) and NOXA were performed in myc- 
(A) and HA-tag (B) immunoprecipitates (IP) or whole cell lysates.  
Pat1-2 cells were transfected with myc-NOXA or left untransfected (ctrl). IB-
analyses of K48-linked polyubiquitin (UbK48) and NOXA were performed in myc-
tag IPs or whole cell lysates (C). 
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To exclude a detection of K48-linked polyubiquitin of potential binding partners of 
NOXA, lysates were denaturated by boiling in 1% SDS prior to immunoprecipitation 
(IP). Subsequent IB-analysis detected K48-polyubiquitylation of wild-type NOXA 
(NOXA-wt). In contrast, no polyubiquitin chains were detected on NOXA-K0, a 
construct that cannot be ubiquitylated because it lacks all lysine residues. 
Confirming these in vitro analyses, NOXA ubiquitylation in tumour cells derived from 
melanoma patients revealed a significant increase in ubiquitylation of ectopically 
overexpressed myc-NOXA in Pat2 compared to Pat1 tumour cells (Fig. 3.6C).  
Taken together, these data provide strong evidence for the elevated ubiquitylation 
and proteasomal degradation of NOXA in bortezomib-sensitive Pat2 tumour cells.  
3.5 The deubiquitylating enzyme (DUB) UCH-L1 is absent 
in bortezomib-sensitive tumour cells 
The turnover of UPS-substrate is regulated by continuous ubiquitylation and 
deubiquitylation involving E3-ubiquitin-ligases and deubiquitylating enzymes (DUBs), 
respectively. The presence of more than 500 E3-ubiquitin-ligases and approximately 
100 DUBs in human cells illustrates the intrinsic specificity of components of the UPS 
for particular cellular substrates. Conceivably, selective manipulation of this 
machinery could affect the stability of specific UPS-substrates. In order to monitor the 
possible alterations of UPS-components, which may impact on NOXA turnover, 
PIQORTM Ubiquitin-PS Microarrays (Miltenyi Biotec) were performed in primary 
melanoma samples (Pat1-3 versus non-malignant primary melanocytes), HL B-cell 
lines (HL B-cell lines L428 and L591 versus the non-malignant control B-cell line 
L1309) and melanoma cell lines (bortezomib-sensitive Colo38 versus the 
bortezomib-resistant SKmel23). The PIQORTM Ubiquitin-PS Microarray is a dual 
colour array that allows the analyses of mRNA expression of more than 1300 genes 
presumed to be involved in UPS regulation. Ratios represent normalized Cy5/Cy3 
ratios of four replicates per gene. Genes that are more than 1.7 up- or down-
regulated (presented as ratios >1.7 or <0.58, respectively) represent putative 
candidate genes. In the present analysis a number of deregulated genes were 
identified in each individual tumour sample. Since accumulation of NOXA upon 
proteasome inhibition was a common feature among the bortezomib-sensitive tumour 
cells tested, the E3-ubiquitin-ligases and DUBs being similarly up- or down-regulated 
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in the tumour samples were first assumed to be possible candidates responsible for 
the enhanced NOXA ubiquitylation and turnover. After neglecting genes amplified in 
less than 4 of the performed 6 arrays, 31 DUBs (Tab. 5.1A) and 56 RING-domain-
containing proteins as potential E3-ubiquitin-ligases (Tab. 5.1B) and remained in the 
analyses. Given that NOXA ubiquitylation and turnover was enhanced in bortezomib-
sensitive tumour cells, the responsible E3-ubiquitin-ligase should be expressed 
higher the more susceptible the cells are towards bortezomib-treatment (e.g. Pat1 < 
Pat2) and correspondingly the responsible DUB should be expressed less (e.g. Pat1 
> Pat2). Indeed, a strong correlation between the three tumour sample groups was 
observed in the regulation of the Ubiquitin-Carboxy-terminal-hydrolase-L1 (UCH-L1). 
Strikingly, UCH-L1 was the only DUB found to be highly down-regulated in all tested 
bortezomib-sensitive tumour samples including primary melanoma Pat2 tumour cells, 
melanoma cell line Colo38 and HL B-cell lines L428 or L591 (Table 5.1B). To 
illustrate these results, a gene expression profile of DUBs was generated for the 
performed microarrays of melanoma patients and HL B-cell lines (Fig. 3.7A). Further 
protein expression analyses by IB confirmed the loss of expression of UCH-L1 in 
bortezomib-sensitive tumour samples (Fig. 3.7B). 
 
Figure 3.7 | Gene expression profile of selected DUBs. Dual colour 
PIQUOR-UPS-microarray (Miltenyi Biotech) was performed in primary cells 
from melanoma Pat1-3 using non-malignant primary melanocytes as a 
reference and in L428 and L591 HL B-cell lines using the non malignant L1309 
B-cell line as a reference. Green colour indicates down-regulated genes, red 
colour indicates up-regulated genes compared to the reference. Grey colour 
indicates genes that were not amplified (A). IB-analyses of UCH-L1 expression 
in primary cells from melanoma Pat1-3, HL B-cell lines (L428, L591) with the 
corresponding non-malignant control B-cell line (L1309) and melanoma cell 
lines (SKmel23, Colo38). Actin served as a loading control (B). 
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In summary, all of the tumour cells tested, showed that accumulation of NOXA upon 
proteasome inhibition was linked to the simultaneous lack of UCH-L1 expression. 
3.6 The DUB UCH-L1, binds, deubiquitylates and stabilizes 
NOXA in vitro  
UCH-L1 (also called PARK5; PGP 9.5) possesses K48-dependent ubiquitin 
hydrolase activity and has been involved in the onset of human diseases including 
cancer and neurological disorders. However, the substrates of UCH-L1 are unknown 
and its precise function and the relevant cellular regulatory mechanisms are still 
unclear. To investigate whether UCH-L1 is a DUB of NOXA and thereby responsible 
for stabilizing NOXA protein, myc-NOXA was overexpressed in HEK293FT cells 
either together with GFP or GFP-UCH-L1. Strikingly, the expression levels of 
ectopically expressed myc-NOXA were significantly elevated by co-expression of 
GFP-UCH-L1 but not GFP alone. A similar pattern of NOXA protein expression was 
obtained when cells expressing myc-NOXA and GFP were additionally treated with 
bortezomib, highlighting the continuous degradation of myc-NOXA in the absence of 
UCH-L1 (Fig. 3.8). 
 
 
Figure 3.8 | UCH-L1 stabilizes NOXA. HEK293FT cells were transfected with 
pCDNA3.1 or myc-NOXA-wt and GFP-UCH-L1 or GFP, as indicated and 
treated with 50 nM bortezomib (10 hours after transfection) for 4 hours, as 
indicated. IB-analyses of indicated proteins were performed in whole cell 
lysates. 
To investigate if NOXA and UCH-L1 directly interact, co-IP-analyses with ectopically 
overexpressed myc-NOXA with GFP-UCH-L1 or GFP alone were performed in 
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HEK293 FT cells. GFP-specific IP analyses revealed that myc-NOXA co-precipitated 
with GFP-UCH-L1 but not GFP alone (Fig. 3.9A) providing the first evidence that 
UCH-L1 directly interacted with NOXA.  
 
 
 
Figure 3.9 | UCH-L1 and NOXA are direct interaction partners. HEK293 FT 
cells were co-transfected with indicated expression plasmids. 24 hours after 
transfection IB-analyses of the indicated proteins were performed in GFP-IPs or 
whole cell lysates (A). HEK293 FT cells were transfected with myc-NOXA-wt, 
myc-NOXA-K0 or myc-XIAP and treated with 100 nM bortezomib for 4 hours. 
Lysates were incubated with either recombinant UCH-L1-GST or UCH-L3-His. 
IB-analyses of the indicated proteins were performed in myc-tag-IPs or whole 
cell lysates (B).  *unspecific band resulting from the GFP-antibody. 
Additionally, cell-free binding assays were performed in cell lysates of HEK293FT 
cells overexpressing myc-NOXA-wt, myc-NOXA-K0 (as a non-ubiquitylated control) 
or myc-XIAP (as an unspecific ubiquitylated control). 8 hours after transfection cells 
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where treated with 50 nM bortezomib for 24 hours to accumulate the ubiquitylated 
proteins. Whole cell lysates were further incubated with either recombinant GST-
UCH-L1 or HIS-UCH-L3, another member of the UCH-family that shares 51% of 
amino acid sequence identity with UCH-L1. Unlike UCH-L3, UCH-L1 was capable of 
binding NOXA but not XIAP (which has been shown to be K48-ubiquitylated), 
demonstrating the specific interaction of UCH-L1 with NOXA. This interaction was 
likely dependent on NOXA ubiquitylation since almost no NOXA-K0 was co-
precipitated with UCH-L1 (Fig. 3.9B). 
The potency of UCH-L1 in hydrolyzing the polyubiquitin chains of NOXA was further 
investigated with an in vitro deubiquitylation assay. HEK293FT cells were transfected 
with myc-NOXA or HA-NOXA and treated with 50 nM bortezomib (8 hours post 
transfection) for 24 hours. Lysates were incubated with recombinant GST-UCH-L1 
and IB-analyses of K48-polyubiquitin were performed in either HA- or myc-tag 
specific immunoprecipitates. As expected, recombinant UCH-L1 protein was able to 
potently deubiquitylate NOXA in a time dependent manner (Fig. 3.10).  
 
 
Figure 3.10 | UCH-L1 deubiquitylates NOXA in vitro. HEK293 FT cells were 
transfected with HA- or myc-NOXA-wt. Lysates were incubated with 
recombinant UCH-L1-GST for indicated time periods. 24 hours after transfection 
IB-analyses of K48-linked polyubiquitin (UbK48) and NOXA were performed in 
myc- or HA-tag-IPs (A,B respectively) or whole cell lysates. 
To confirm the data obtained from overexpressed tagged-NOXA, the ability of UCH-
L1 to stabilize endogenous NOXA was determined by fluorescence microscopy and 
FACS-analyses. Bortezomib-sensitive Pat2 tumour cells lacking endogenous UCH-
L1 expression were transfected with GFP-UCH-L1 and endogenous NOXA was 
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immunostained. Fig. 3.11A shows the accumulation of endogenous NOXA (red) in 
microscopic analyses only in cells co-expressing GFP-UCH-L1 (green). To assess 
the statistical significance FACS-analyses were performed in cells overexpressing 
GFP, wild-type GFP-UCH-L1 (GFP-UCH-L1-wt) and mutant GFP-UCH-L1 (GFP-
UCH-L1D176N possessing only 2.5 % enzymatic activity of UCH-L1-wt). Endogenous 
NOXA was immunostained (red) and its intensity was measured by PerCP-mean in 
GFP-positive cells. Expression levels of endogenous NOXA in GFP-UCH-L1-wt or 
GFP-UCH-L1D176N are presented as fold induction to the expression level in GFP-
expressing cells. A significant accumulation of endogenous NOXA was observed 
only when GFP-UCH-L1-wt but not when the mutant UCH-L1D176N was expressed, 
indicating that the enzymatic activity of UCH-L1 is required for the accumulation of 
endogenous NOXA (Fig. 3.11B).  
 
 
Figure 3.11 | UCH-L1 stabilizes endogenous NOXA. Immunofluorescence 
analysis of primary cells of melanoma Pat2 transfected with GFP-UCH-L1 
(green) for 24 hours and stained for endogenous NOXA (red) and dapi (blue) 
(A) and FACS-analyses of primary cells from melanoma Pat2 transfected with 
GFP, GFP-UCH-L1-wt (wt) or GFP-UCH-L1D176N (D176N) for 24 hours and 
stained for endogenous NOXA. Expression levels of endogenous NOXA in 
GFP-UCH-L1-wt or GFP-UCH-L1D176N expressing cells are presented as fold 
induction to the expression level in GFP-expressing cells. Data are presented 
as mean +/- SEM of 3 independent experiments, with statistical significance 
determined by Students t-test (B). IB-blot analyses of NOXA and UCH-L1 
expression in primary cells from melanoma Pat1 transfected with scr-siRNA or 
siUCH-L1 for 48 hours. Actin served as a loading control (C). 
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Consistent with the analyses using overexpressed UCH-L1, specific knock-down of 
UCH-L1 by specific siRNA significantly reduced the expression level of endogenous 
NOXA in UCH-L1 positive Pat1 tumour cells (Fig. 3.11C).  
These data identify UCH-L1 as a specific DUB of NOXA that stabilizes NOXA protein 
through its specific deubiquitylation.  
3.7 UCH-L1-expression correlates with increased NOXA-
expression in tumour tissue sections of melanoma and 
CRC patients 
If UCH-L1 is responsible for stabilizing NOXA, then tumour samples expressing 
UCH-L1 might also exhibit increased expression of NOXA compared with UCH-L1 
negative tumours. In order to address this point, immunohistochemical (IHC)-
analyses of UCH-L1 and NOXA in a cohort of melanoma (81 cases) and CRC (26 
cases) patients were performed in collaboration with the Departments of 
Dermatology (Prof. Dr. C. Mauch), Internal Medicine (PD Dr. Ulrich Hacker) and 
Pathology (Dr. U. Drebber) of the University of Cologne. Figure 3.12A shows a 
representative positive and negative example of IHC staining of NOXA and UCH-L1 
in melanoma patients. Fig. 3.12B illustrates the results of the IHC stainings of all 
patient tissue samples tested. In tumour tissues the expression of UCH-L1 was 
tightly associated with elevated NOXA expression  (96% of melanoma and 100% of 
CRC patients) (Tab. 5.2, 5.3). Interestingly, increased NOXA-expression was also 
observed in tumour samples lacking UCH-L1 expression indicating the involvement 
of UCH-L1-independent regulatory mechanisms controlling NOXA expression such 
as its transcriptional regulation.  
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Figure 3.12 | UCH-L1 expression is correlated with increased NOXA 
expression in melanoma and CRC patients. Representative 
immunohistochemical staining (IHC) of UCH-L1 and NOXA in tumour sections 
derived from melanoma patient number 20 (UCH-L1++; NOXA+++) and patient 
number 54 (UCH-L1-; NOXA-) (A). NOXA and UCH-L1-expression in IHC in 81 
melanoma patients (black circles) and 26 CRC patients (grey circles). 
Intensities of specific staining were arbitrarily set as the following: -, no 
expression; +, low expression; ++, moderate expression; +++, strong 
expression (B). Microscopic analyses of IHC-stainings of tumour sections from 
melanoma and CRC patients used to generate Fig 3.14B were performed by 
Dr. P. Zigrino and Dr. U. Drebber, respectively. IHC-stainings were carried out 
by Dr. P Zigrino. 
Furthermore, these data demonstrate that UCH-L1 expression is missing in the 
majority of tumour samples tested (70%). Importantly, UCH-L1 has previously been 
shown to be epigenetically silenced in diverse tumour entities. Accordingly, 
pharmacological unmasking approaches such as demethylating agents and histone 
deacetylase inhibitors (HDACi) have been shown to induce UCH-L1 expression and 
promote cytotoxic actions. To investigate if UCH-L1 expression could be restored by 
preventing epigenetic silencing, Pat2 tumour cells were treated with increasing 
concentration of the demethylating agent 5-aza-2(')-deoxycytidine or the HDACi 
Trichostatin A. The following IB-analyses demonstrate a significant up-regulation of 
UCH-L1 which was followed by NOXA accumulation (Fig. 3.13).    
These results provide strong evidence for a prevalent epigenetic silencing of UCH-L1 
leading to the destabilization of NOXA. 
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Figure 3.13 | UCH-L1 depletion is caused by epigenetic silencing. Primary 
cells from melanoma Pat2 were treated with the indicated concentrations of 5-
Aza-2´Deoxycytidine for 4 days (A) or Trichostatin A for 24 hours (B). IB-
analyses of UCH-L1 and NOXA expression was performed in whole cell lysates. 
Actin served as a loading control.  
3.8 UCH-L1 depletion is associated with chemoresistance 
in tumour cells  
NOXA has initially been described as a critical factor in mediating genotoxic stress-
induced apoptosis. Thus, UCH-L1 expression might interfere with the cellular 
response to genotoxic stress. To investigate this hypothesis primary cells from 
melanoma patients (Pat1-3), melanoma cell lines (Colo38, SKmel23, SKmel28, MV3, 
WM164, MeWo) and HL B-cell lines (L428, L591) with the non-malignant control B-
cell line (L1309) were analysed for UCH-L1-expression by IB (Fig. 3.14A) and their 
susceptibility to bortezomib- (Fig. 3.14B) or doxorubicin- (Fig. 3.14C) treatment was 
analysed in a cell viability assay. Strikingly, increased susceptibility to proteasome 
inhibition and the loss of UCH-L1 expression were accompanied by simultaneous 
chemoresistance to the DNA damaging agent doxorubicin. 
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Figure 3.14 | UCH-L1 depletion is associated with chemoresistance. IB-
analyses of UCH-L1 expression in the indicated cells. Actin served as a loading 
control (A). Primary cells from melanoma patients (Pat1-3), melanoma- (Mel) 
cell lines (Colo38, Skmel23, Skmel28, MV3, WM164, Mewo), HL B-cell lines 
(L428, L591) and a control B-cell line (L1309) were treated with bortezomib 
(Pat1-3, Mel 50 nM, HL 10 nM) (B) or doxorubicin (0,5 µM) (C). Toxicity was 
measured by XTT assay (Pat1-3, Mel) or counting of trypan blue positive cells 
(HL). Data are presented as mean +/- SEM of 3 independent experiments.  
To further assess the role of UCH-L1-depletion in conferring chemoresistance, UCH-
L1 was depleted by specific siRNA in UCH-L1 positive Pat1 cells and treated with 
doxorubicin. The following cell viability assay revealed that down-regulation of UCH-
L1 in UCH-L1-expressing Pat1 cells increased the resistance to the DNA damaging 
agent doxorubicin (Fig. 15A) as a result of inefficient NOXA accumulation, shown by 
IB-analysis. The impact of UCH-L1 activity on DNA damage-induced NOXA 
accumulation was further investigated using LDN-57444, a potent inhibitor of UCH-L1 
enzymatic activity. Co-treatment of Pat1 cells with LDN-57444 significantly reduced 
the accumulation of NOXA in response to DNA damage induced by doxorubicin, 
additionally supporting our findings that UCH-L1 is a key regulator of NOXA stability. 
(Fig. 15B) 
Taken together, these data identify UCH-L1 as an important regulator of the DNA 
damage-induced apoptosis by stabilizing the DNA damage-induced NOXA protein. 
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Fig. 3.15 | Decreased UCH-L1 activity results in increased chemo-
resistence accompanied by decreased NOXA accumulation. Primary cells 
from melanoma Pat1 were transfected with scr-siRNA or siUCH-L1. IB-blot 
analyses of UCH-L1 and NOXA expression and cell viability analyses were 
performed after treatment with doxorubicin (0.5 µM, 8 hours for IB-analysis; 2 
µM, 24 hours for viability analysis) 24 hours after transfection. Data of cell 
viability analysis are presented as mean +/- SEM of 1 representative 
experiment in 6 replicates, with statistical significance determined by Students t-
test. (A).  IB-analyses of NOXA and UCH-L1 expression in Pat1 cells treated 
with doxorubicin and LDN-57444 for 8 hours. Actin served as a loading control 
(B). 
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4 Discussion 
4.1 NOXA accumulation as a key event in proteasome 
inhibition-induced apoptosis  
In 2000, Weinberg and Hanahan defined six hallmarks of cancer describing biological 
capabilities acquired during the multistep development of human tumours. They 
include sustaining proliferative signalling, evading growth suppressors, enabling 
replicative immortality, inducing angiogenesis, activating invasion and metastasis and 
resisting cell death. Ten years later they updated this list to also include 
reprogramming of energy metabolism and evading immune destruction (Hanahan 
and Weinberg, 2000, 2011).  
Conventional chemotherapy used to treat cancer usually engages the mitochondrial 
apoptotic pathway. Not surprisingly, its deregulation results in treatment resistance. 
In line with several publications the present work shows that the proteasome inhibitor 
bortezomib can promote direct cytotoxicity only in a cohort of tumour samples 
including primary tumour cells derived from melanoma patients, melanoma cell lines, 
HL cell lines and CRC cell lines by inducing the mitochondrial apoptotic pathway 
(Fernandez et al., 2005; Herrmann et al., 1998; Lopes et al., 1997; Qin et al., 2005) 
(Fig. 3.1-2). Analyses of BH3-only proteins, as central regulators of mitochondrial 
outer membrane permeabilization (MOMP), identified NOXA as the key mediator of 
proteasome inhibition-induced apoptosis (Fig 3.3). Congruent with the present 
results, the majority of research aiming to unravel the molecular mechanism of 
apoptosis-induction upon proteasome inhibition recognized NOXA as an essential 
factor and induction of NOXA has been reported upon proteasome inhibition in 
tumour versus healthy tissues (Gomez-Bougie et al., 2007; Qin et al., 2005). 
Conversely, when NOXA was down-regulated by siRNA, a significant reduction in the 
susceptibility to bortezomib was observed in initially sensitive tumour cells 
(Fernandez et al., 2005; Gomez-Bougie et al., 2007; Qin et al., 2005).  
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However, the underlying molecular mechanisms giving rise to the selective 
accumulation of NOXA in the above mentioned cohort of tumour samples are largely 
unknown.  
In 1990 Hijikata et al. isolated the first NOXA cDNA clone from an adult T-cell 
leukemia (ATL) library (Hijikata et al., 1990; Ploner et al., 2009). The transcript was 
up-regulated by phorbol 12-myristate 13-acetate (PMA) and was therefore called 
ATL-derived PMA-responsive gene (APR). Later on it was given the Human Genome 
Organisation (HUGO) designation PMA-induced protein 1 (PMAIP1) (Ploner et al., 
2009). A differential display approach using mRNA from γ-irradiated wild type (wt) 
and IRF-1/p53 double-deficient MEFs rediscovered APR/PMAIP1 as a 103 amino-
acid protein, which the authors termed NOXA (Latin for damage). Further sequence 
analyses identified a Bcl2 homology (BH) domain 3 and NOXA was characterized as 
a novel BH3-only protein family (Oda et al., 2000).  
Recent biochemical analyses employing cell-free systems described NOXA as a 
“sensitizer” BH3-only protein with weak pro-apoptotic activity capable of initiating cell 
death only in conjunction with other BH3-only members (Chen et al., 2005). In 
contrast, the present data suggest that accumulation of NOXA alone might be 
sufficient to initiate the mitochondrial apoptotic pathway resulting in apoptotic cell 
death (Fig. 3.2). These data are in agreement with the initial report demonstrating 
that NOXA is capable of directly initiating MOMP and cell death (Hallaert et al., 2007; 
Mackus et al., 2005; Zaher et al., 2009). Since NOXA has the most restricted 
potential to neutralize certain anti-apoptotic members of the Bcl2 protein family such 
as MCL1 and A1, the differential expression levels of NOXA binding partners could 
potentially impact on the susceptibility to NOXA action (Chen et al., 2005). 
Accordingly, cell free analyses of isolated mitochondria overexpressing MCL1 have 
been shown to be particularly sensitive or "primed" to NOXA-induced MOMP (Certo 
et al., 2006). 
A model for the NOXA dependent induction of MOMP upon proteasome inhibition 
has been proposed in Multiple Myeloma. In this model MCL-1 protein sequesters the 
‘‘direct activator’’ BH3-only protein BIM. Under bortezomib-treatment, induction of the 
‘‘sensitizer’’ BH3-only protein NOXA allows the displacement of the ‘‘direct activator’’ 
BIM, which is now able to activate BAX/BAK-dependent MOMP (Fig. 4.1) (Gomez-
Bougie et al., 2007).  
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Regardless of its pro-apoptotic properties, the critical role of NOXA in fine-tuning 
BAX/BAK-dependent MOMP and cell death is widely accepted. Particularly, NOXA-
dependent cell death appears to be highly relevant for apoptosis induction in 
malignant or highly proliferating versus primary or differentiated cells, implicating 
NOXA as a tumour suppressor or valuable therapeutic target (Fernandez et al., 2005; 
Qin et al., 2005). However, in the present analysis NOXA expression levels did not 
correlate with overall or disease-free survival in human melanoma and colon 
carcinoma patients (Tab. 5.2-3). This is in line with a previous report showing that 
deregulation of NOXA expression is not associated with disease development in 
acute lymphoblastic leukaemia (Ploner et al., 2009).  
Albeit a possible involvement of NOXA in carcinogenesis remains to be shown, its 
importance as a drug target is becoming increasingly evident. Accordingly NOXA is 
essential in p53-induced apoptosis triggered by classical anticancer agents such as 
etoposide or γ-irradiation but also for tumour cell death triggered by the cyclin-
dependent kinase inhibitor R-roscovitine, histone deacetylases inhibitiors (HDACi), 
and in particular, by proteasome inhibition (Dransfeld et al., 2007; Hallaert et al., 
2007; Oda et al., 2000; Qin et al., 2005). By conclusively showing the impact of the 
regulation of NOXA expression on the chemosusceptibility of tumour cells the 
present findings clearly support the idea that NOXA represents an important anti-
cancer target.   
Figure 4.1 | Model of the 
interplay between anti-
apoptotic and pro-apoptotic 
molecules of the Bcl-2 family 
under bortezomib-treatment. 
In myeloma cells, Mcl-1 protein 
sequesters the ‘‘direct activator’’ 
BH3-only protein BIM. Under 
bortezomib-treatment, induction 
of the ‘‘sensitizer’’ BH3-only 
NOXA allows the displacement 
of the ‘‘direct activator’’ BIM, 
which is now able to activate 
BAX/BAK-dependent MOMP. 
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4.2 Post-transcriptional regulation of NOXA by the UPS  
Although the impact of NOXA on chemosusceptibilty in cancer is indisputable, most 
previous work suggested that chemotherapy including proteasome inhibitors targets 
NOXA’s transcriptional regulation (Fernandez et al., 2005; Perez-Galan et al., 2006; 
Qin et al., 2005). Accordingly, NOXA accumulation upon proteasome inhibition is 
supposed to be due to the stabilization of its transcription factors, the best described 
of which is p53. Interestingly, initial publications show that cell death induced by 
proteasome inhibition occurs independently of p53 (Herrmann et al., 1998; Lopes et 
al., 1997) and more recent publications confirm NOXA accumulation upon 
proteasome inhibition to be independent of p53 (Nikiforov et al., 2007; Qin et al., 
2005).  
NOXA transcription is also regulated by HIF1-α (Kim et al., 2004a), E2F-1 (Hershko 
and Ginsberg, 2004) and c-myc (Nikiforov et al., 2007). Importantly Nikiforov et. al, 
2007 demonstrated that NOXA mRNA accumulation upon proteasome inhibition is 
independent of p53, HIF1-α and E2F, but relies on the activity of c-myc. Nevertheless 
complete reliance of NOXA protein accumulation for c-myc has not been shown and 
additional regulatory mechanisms resulting in NOXA accumulation upon proteasome 
inhibition could not be excluded.  
The present analysis showed that in a cohort of tumour samples NOXA accumulation 
was not a result of transcriptional up-regulation. Further analyses conclusively 
demonstrated enhanced NOXA-ubiquitylation and degradation by the ubiquitin-
proteasome system (UPS) in this tumour cohort highlighting an as yet unrecognized 
alteration of NOXA regulation in cancer (Fig. 3.5-6). In line, a recent publication 
confirmed that NOXA can be ubiquitylated (Baou et al., 2010). However any further 
characterization of its biologic or pathobiological significance and the underlying 
molecular mechanism are still lacking.  
4.3 Increased NOXA degradation as a result of lacking 
UCH-L1 expression, the specific DUB of NOXA 
Analysis of components of the UPS identified the deubiquitylating enzyme UCH-L1 
as a possible candidate responsible for the variation in NOXA stability (Fig. 3.8-3.12). 
Discussion 
 54 
The present data clearly identified UCH-L1 as the specific deubiquitylating enzyme 
(DUB) of NOXA. UCH-L1 directly interacts and stabilizes NOXA by removing the K48 
linked polyubiquitin chains that mark NOXA for proteasomal degradation (Fig. 3.8-
3.11).  
UCH-L1 was initially reported to play a role in the development and progression of 
Parkinson´s disease by stabilization of α-synuclein levels. Of note, UCH-L1 has 
meanwhile been described to posses an ubiquitin ligase activity. The identification of 
the ligase activity is based on the initial accumulation of polyubiquitylated α-synuclein 
upon transient overexpression of UCH-L1, followed by a rapid decrease in high-
molecular α-synuclein. Detailed analyses indicated that K63 might be the primary 
ubiquityl acceptor residue of UCH-L1, in contrast to the E2/E3 ligases involved in 
proteasomal degradation, which ubiquitylate K48 (Liu et al., 2002).  
However, there is no further evidence of a ligase activity of UCH-L1, and since it is 
only observed at high enzyme concentrations in vitro the relevance of these findings 
is debatable. In contrast the deubiquitylating activity and thus involvement in the UPS 
pathway of UCH-L1 has been widely accepted. 
Our analyses of melanoma and colon carcinoma patient samples revealed a strong 
correlation of NOXA and UCH-L1 expression (Fig. 3.12). Whenever UCH-L1 was 
expressed, a high level of NOXA expression was detected supporting the proposed 
model of UCH-L1-mediated stabilization of NOXA in vivo. However, high levels of 
NOXA expression were also found in patients where UCH-L1 was not detectable, 
implicating additional regulatory mechanisms involved in NOXA expression, such as 
transcriptional regulation. NOXA transcription is reportedly regulated by p53. 
Certainly, p53 amplification is not a common feature of tumour cells, in fact, p53 is 
inactive in up to 50% of human cancers (Hollstein et al., 1994). The transcription 
factor c-myc, shown to induce NOXA transcription (Nikiforov et al., 2007), might be a 
promising candidate for enhanced NOXA expression since it is highly active in the 
vast majority of tumour samples (Nesbit et al., 1999). However final confirmation of 
this awaits further analyses.  
It is also noted that UCH-L1 expression is lacking in 69% of melanoma patients and 
in 64% of colorectal carcinoma patients. Congruently, UCH-L1 has previously been 
shown to be epigenetically silenced in various tumour entities such as hepatocellular 
carcinoma (Yu et al., 2008), pancreatic cancer (Sato et al., 2003), gastric cancer 
(Yamashita et al., 2006), breast cancer (Xiang et al., 2012) and colon carcinoma 
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(Fukutomi et al., 2007). Accordingly, pharmacological unmasking approaches such 
as demethylating agents and HDACis have been shown to induce UCH-L1 
expression and promote cytotoxic actions. However, the mechanism of UCH-L1-
promoted cytotoxic effects was not addressed.  
In this work it was demonstrated that re-expression of UCH-L1 in UCH-L1 negative 
Pat2 cells through treatment with HDACi was followed by an accumulation of NOXA 
(Fig. 3.13). In line with this HDACi are already described to induce NOXA expression, 
and strikingly, siRNA mediated knock-down of NOXA reduced HDACi-mediated cell 
death (Inoue et al., 2007). Conversely, siRNA mediated knock-down of the NOXA 
antagonist MCL1 potentiated HDACi-mediated apoptosis (Inoue et al., 2008). Finally, 
mice lacking the MCL1 specific E3-ubiquitin ligase MULE (resulting in enhanced 
MCL1-stability) are protected from HDACi-mediated apoptosis (Jing et al., 2011). In 
conclusion, the ratio of NOXA and MCL1 expression determines the susceptibility 
toward HDACi-mediated apoptosis while NOXA accumulation seems to be an 
essential event.  
The present data provide the first evidence that the reactivation of epigenetically 
silenced UCH-L1 is responsible for the accumulation of NOXA and thereby plays an 
essential role in HDACi-mediated cell death.  
4.4 UCH-L1 as a modulator of apoptosis 
Several publications indicate a contribution of UCH-L1 in germ cell apoptosis and 
spermatogenesis (Fraile et al., 1996; Kon et al., 1999; Kwon et al., 2003; Martin et 
al., 1995). Mice lacking UCH- L1 expression (gad (gracile axonal dystrophy) mice) 
exhibit defects in spermatogenesis, which are thought to be associated with impaired 
germ cell apoptosis (Kim et al., 2004b). Moreover, apoptosis induced by neuronal 
injury is supressed by up to 70% in gad mice (Harada et al., 2004). Remarkably, a 
comparable insufficiency in apoptosis upon neuronal injury is observed in NOXA 
knock-out mice (Kiryu-Seo et al., 2005). On the other hand, transgenic mice 
overexpressing EF1α promoter-driven UCH-L1 in the testis are sterile due to a block 
in spermatogenesis at an early stage (pachytene) of meiosis. This turned out to be 
the result of accelerated apoptosis suggesting UCH-L1 as a DUB with pro-apoptotic 
functions (Wang et al., 2006).  
Discussion 
 56 
In line with these observations, recent publications also point at a role of UCH-L1 in 
tumour cell apoptosis. UCH-L1 is reported to play an essential role in tumour cell 
invasion in melanoma patients through up-regulation of Akt-signalling (Kim et al., 
2009). Furthermore, it has been shown that overexpression of UCH-L1 induces 
apoptosis in breast cancer and gastric cancer (Kim et al., 2011; Wang et al., 2008). 
Apoptosis induction in breast cancer cells upon overexpression of UCH-L1 is thought 
to be due to the stabilization of p53 and associated induction of G0/G1 cell cycle 
arrest and apoptosis (Xiang et al., 2012). However, no evidence for deubiquitylation 
and post-translational stabilization of any of these factors has been demonstrated 
and the mechanistic insight as to how UCH-L1 interferes with the apoptotic pathway 
is still lacking. In the present work NOXA was clearly demonstrated as a target of 
UCH-L1 that mediates UCH-L1-potentiated apoptosis.   
4.5 UCH-L1 as an important component of the DNA 
damage response by stabilization of NOXA 
NOXA has been initially described as a critical factor mediating genotoxic stress-
induced apoptosis. Upon DNA damage NOXA is transcriptionally up-regulated, 
resulting in the activation of the mitochondrial apoptotic pathway (Oda et al., 2000). 
Here it is demonstrated, that besides the transcriptional up-regulation of NOXA, 
tumour cells rely on functional UCH-L1 in order to stabilize NOXA protein and 
sufficiently induce apoptosis in response to genotoxic stress (Fig. 3.14). Accordingly, 
cells lacking UCH-L1 expression failed to accumulate NOXA protein after treatment 
with DNA damaging agents, even though NOXA was transcriptionally activated (Fig. 
3.4). Furthermore, down-regulation of UCH-L1 expression or the inhibition of its 
deubiquitylating activity in DNA damage-susceptible tumour cells attenuated the 
cytotoxic activity of DNA damaging agents (Fig. 3.15) resulting from a reduction in 
DNA damage-induced NOXA accumulation.  
In addition to biochemical and cell biological analyses carried out in human tissue 
cultures, the impact of UCH-L1 on apoptosis was further demonstrated in 
Caenhorhabditis elegans (C.elegans) in cooperation with the group of Prof. Thorsten 
Hoppe (University of Cologne). DNA damage induced by ionizing radiation (IR) 
initiates several cellular responses in C.elegans, including germ cell apoptosis. On 
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the other hand, dysfunction of DNA damage responsive genes has been shown to 
enhance the embryonic lethality of IR and genomic instability (Gartner et al., 2000). 
Strikingly, RNAi mediated knock-down of the C.elegans UCH-L1 homologues ubh-2 
or ubh-3 resulted in reduced apoptosis and embryonal hypersensitivity in response to 
IR (Michael Schell, Leena Ackermann, respectively).  
These data confirm our analyses and highlight the conserved role of UCH-L1 in the 
DNA damage-induced apoptotic pathway. 
4.6 Conclusion 
In conclusion, the present data showed for the first time, that UCH-L1 is an important 
component of the DNA damage response and impacts on the susceptibility of cancer 
cells toward chemotherapy by stabilizing NOXA. DNA damage-inducing chemo-
therapy usually results in the transcriptional up-regulation of NOXA. NOXA protein is 
immediately marked for proteasomal degradation with K48-polyubiqutin chains by an 
as yet unknown ubiquitin ligase.  
In UCH-L1 positive cells, UCH-L1 deubiquitylates and stabilizes NOXA resulting in 
NOXA-triggered cell death.  
In contrast, in cells lacking UCH-L1, NOXA is markedly unstable as a result of 
continuous degradation by the UPS. Accordingly, DNA damage-inducing chemo-
therapy does not result in a sufficient accumulation of NOXA protein and thus does 
not induce cell death (Fig. 4.1). 
Notably, NOXA executes its pro-apoptotic action through specific binding to its anti-
apoptotic counterpart, MCL1. Two independent recent reports identified the specific 
DUB and ubiquitin ligase of MCL1 to substantially impact on MCL1 protein turnover 
and apoptosis in response to cytostatic treatments of cancer (Inuzuka et al., 2011; 
Wertz et al., 2011). In line with these observations, increasing and maintaining NOXA 
protein levels by promoting UCH-L1 expression may hold promise in the treatment of 
chemoresistant cancer. 
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Figure 4.1 | Conclusion. DNA damage induced by chemotherapy results in the 
transcriptional up-regulation of NOXA. By an as yet unknown mechanism 
NOXA gets polyubiquitylated. In UCH-L1 positive cells, UCH-L1 deubiquitylates 
NOXA and liberated NOXA is able to induce mitochondrial outer membrane 
permeabilization (MOMP) and thus apoptotic cell death (left). In UCH-L1 
negative cells, ubiquitylated NOXA is continuously degraded by the proteasome 
and thus is not able to induce mitochondrial apoptosis (right). 
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6 Appendix 
6.1 Microarray 
Table 5.1 | Gene based list of mRNA expression. Dual colour PIQUOR-UPS-
microarray (Miltenyi) was performed in Pat1-3 cells using non-malignant melanocytes as a 
reference, bortezomib sensitive Colo38 melanoma cells using bortezomib resistant SKmel23 
melanoma cells as a reference and L428/L591 Hodgkin Lymphoma cells using non-malingnant 
L1309 B-cells as a reference. List represents a selection of DUBs (A) and RING-domain 
containing proteins (B) which were amplified in at least 4 of 6 assays. Ratios represent 
normalized Cy5/Cy3 ratios of 4 replicates per gene. Genes that are >1.7 up- or down- regulated 
(ratio>1.7 and ratio<0.58, respectively) represent putative candidate genes which are 
significantly dysregulated in comparison to the control.  n.a.-not amplified. 
 
 
 
L591 
 n.a. 
 0.40 
0.22 
 0.62 
 1.41 
n.a. 
 n.a. 
n.a. 
n.a. 
 1.89 
n.a. 
 0.93 
 n.a. 
 n.a. 
 1.02 
 0.84 
0.96 
n.a. 
 n.a. 
 1.30 
 0.88 
0.46 
0.49 
 n.a. 
0.65 
 n.a. 
 n.a. 
 1.74 
 0.72 
 0.61 
L428 
0.58
0.49
0.20 
0.64
0.99
1.57 
0.80
0.61 
0.88 
1.46
n.a. 
1.65
0.79
0.82
0.80
0.88
1.10 
1.07 
0.75
1.30
0.97
0.53 
0.47 
1.11
0.63 
0.62
0.85
1.15
0.66
0.74
1.23 
Colo38 
n.a. 
n.a. 
 
1,42
n.a. 
n.a. 
n.a.
n.a. 
n.a. 
n.a. 
n.a. 
1.30 
n.a. 
n.a. 
n.a.
n.a. 
1,37 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 1.31 
Name UniProt/trEMBL RefSeq Pat1  Pat2  Pat3  
BAP1 Q92560 Q6LEM0 Q7Z5E8 NM_004656 0,5 0.50 0.57 
CYLD 
Q9NQC7 O94934 Q7L3N6  
Q96EH0 Q9NZX9 NM_015247 2,14 1,1 0,97 
UCH-L1 P09936 Q71UM0 NM_004181 0.65 0.06 0.23 0.23
UCH-L3-4 P15374 Q5TBK8 Q6IBE9 NM_006002 3.47 0.89 1.05 
UCH-L5 
Q9Y5K5 Q9UQN2 Q9P0I3  
Q9H1W5 Q5LJA6 Q5LJA7  
Q8TBS4 Q96BJ9 NM_015984 1.54 1.49 1.43 
USP1 O94782 Q9UFR0 Q9UNJ3 NM_003368 4.85 3.67 2.78 
USP3 Q9Y6I4 Q9Y2R8 NM_006537 1.09 1.51 1.33 
USP4 Q13107 O43452 O43453 NM_003363 1.22 1.35 1.28 
USP5 P45974 Q96J22 NM_003481 0.69 0.94 0.72 
USP7 Q93009 NM_003470 1.62 1.65 1.19 
USP8 
P40818 Q7Z3U2 Q86VA0  
Q8IWI7 NM_005154 0.85 1.16 1.45 
USP10 Q14694 Q9NSL7 Q9BWG7 NM_005153 1.28 1.28 0.92 
USP11 P51784 Q9BWE1 Q8IUG6 NM_004651 0.75 0.74 0.61 
USP13 Q92995 NM_003940 0.93 0.93 0.80 
USP14 P54578 NM_005151 1.41 1.09 1.10 
USP15 Q9Y4E8 Q9HCA6 Q9UNP0 Q9Y5B5 NM_006313 1.09 1.44 n.a. 
USP16 Q9Y5T5 Q8NEL3 
NM_001001992 NM_001032410 
NM_006447 2.31 1.42 1.22 
USP18-  
USP4 Q9UMW8 Q9NY71 Q70BM7 NM_017414 0.32 0.71 0.44 
USP19 O94966 NM_006677 0.83 0.86 0.85 
USP22 Q9UPT9 - 0.80 1.67 1.44 
USP24 
Q9UPU5 Q9NXD1 Q6ZSY2  
Q8N2Y4 - 1.88 1.63 1.68 
USP32_1 Q9BX85 Q8NFA0 Q9Y591 NM_032582 2.12 1.53 2.96 
USP33 
Q9UPQ5 Q9H9F0 Q8TEY7  
Q8TEY6 Q96AV6 NM_015017 0.93 n.a. 1.42 
USP34 
O60316 O94834 Q8TBW2  
Q8N3T9 Q9UGA1 Q3B777  
Q6P6C9 Q70CQ2 Q7L8P6 NM_014709 1.17 1.57 n.a. n.a.
USP35 Q9P2H5 - 0.93 0.87 1.26 
USP36 Q9P275 Q8NDM8 Q9NVC8 NM_025090 0.81 0.80 1.01 
USP37 Q9HCH8 Q86T82 NM_020935 1.37 1.55 1.24 
USP39 
Q9H381 Q96RK9 Q9BV89  
Q53GS9 Q6NX47 Q9P050  
Q9Y310 NM_006590 1.04 1.12 1.04 
USP44 Q9H0E7 NM_032147 1.63 1.25 0.93 
USP48_2 
Q96F64 Q9H5N3 Q9H5T7  
Q8N3F6 Q9NUJ6 Q9NXR0  
Q96IQ3 Q86UV5 Q2M3I4 Q NM_032236 1.47 1.06 1.43 
USP49 Q96CK4 Q70CQ1 NM_018561 0.61 1.10 0.88 
 
n.a.
n.a.
n.a. 
n.a.
n.a.
n.a.
A
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      Pat1 Pat2 Pat3 Colo38 L428 L591 
RNF138 Q9UKI6 Q9H8K2 Q8WVD3 Q9UF87 NM_016271 NM_198128 9.01 1.86 n.a.   n.a. 1.23 1.51 
BRCA1 P38398 
NM_007294 NM_007297 
NM_007298 NM_007299 
NM_007300 NR_027676 0.72 0.94  0.83 0.63  0.82 0.64  
BARD1 Q99728 O43574 NM_000465 1.86 1.74 1.03 0.64  0.95 0.63 
RNF8 O76064 NM_003958 NM_183078 0.88 0.89 0.90 0.53 0.50 0.49  
ITCH 
O43584 Q96J02 Q96F66 Q9BY75 
Q9H451 Q9H4U5 Q5TEL0 NM_031483 0.63 1.24 1.74  0.56 0.37 0.50 
HECW1 O15036 Q9HCC7 Q76N89 NM_015052 0.49  0.58 0.57 0.47 0.17  0.42 
NEDD4LA 
O43165 Q9H2W4 Q7Z5F1 Q7Z5F2 
Q7Z5N3 Q8N5A7 Q8WUU9 Q96PU5 
Q9BW58 Q NM_015277 0.09  0.35  1.05  0.73 0.39  0.36 
NEDD4 P46934 NM_006154 NM_198400 0.54 0.90 0.99 0.49 0.30 0.42  
WWP2_1 O00308 Q96CZ2 Q9BWN6 NM_007014 NM_199424 0.56  0.66  0.58   n.a. 0.47 0.72 
CBL P22681 NM_005188 0.96 0.81 0.71  0.47 0.53 0.57 
TRAF4 Q14848 O75615 Q9BUZ4 Q2PJN8 NM_004295 0.86 0.78 1.54  1.07 0.59  0.50  
TRAF5 O00463 NM_004619 NM_145759 1.08 1.31 n.a.  n.a. 0.70 0.84 
TRAF6 Q9Y4K3 Q8NEH5 NM_004620 NM_145803 0.94  0.86 0.85  n.a. 0.82   n.a. 
TAP1 Q03518 Q16149 NM_000593 0.83 0.61 1.32  0.95  0.94 0.79 
PSMB8 P28062 Q29824 Q96J48 NM_004159 NM_148919 0.02  0.39  0.13 1.23 0.51  0.55 
PSMB9 P28065 Q16523 NM_002800 NM_148954 0.04 0.51 0.12 1.37 0.42 0.33 
RFP2 O60858 Q9C021 Q9BQ47 
NM_001007278 
NM_005798 NM_052811 
NM_213590 0.81  0.85 0.86  0.66 0.32 0.36  
TRIM28 
Q93040 O00677 Q13263 Q7Z632 
Q96IM1 NM_005762 0.68 0.92 0.63 0.94 0.77 1.45 
PXMP3 P28328 Q9BW41 Q567S6 NM_000318 1.05 1.04  n.a.  n.a. 0.78 0.87 
RNF40 
O75150 Q9HC82 Q8N615 Q6AHZ6  
Q6N005 Q7L3T6 Q96T18 Q9BSV9 NM_014771 2.86 0.89  0.71 1.17  0.81 0.74 
RFP 
P14373 Q6LA73 Q6NXR9 Q9BZY6  
Q9UJL3 Q5ST26 NM_030950 0.48 0.44 0.50  0.59 0.35 0.45 
RNF19 
Q9Y4Y1 Q9H5H9 Q9UFG0 Q9H8M8  
Q9UFX6 Q9NV58 NM_015435 NM_183419 0.63 0.76 0.79  0.50 0.35  0.40 
UBE3A 
P78355 Q93066 Q05086 Q9UEP4 
Q9UEP5 Q9UEP6 Q9UEP7 Q9UEP8 
Q9UEP9 
NM_000462 NM_130838 
NM_130839 0.90 1.49  1.48 0.71 0.59 0.67 
MKRN3 Q13064 NM_005664 0.51  0.50  0.56 0.39 0.28  0.35  
UBE2T Q9NPD8 NM_014176 2.74 1.70 1.50 1.26  1.71 2.44 
UBE2L3 
P51966 Q9HAV1 P70653 P68036 
104444 NM_003347 NM_198157 0.93  1.42 1.02 1.22  0.56 0.85 
RNF31 
Q9H5F1 Q96EP0 Q86VI2 Q8TEI0  
Q96GB4 Q96NF1 Q9NWD2 NM_017999 0.75  0.75  0.73  n.a.   n.a. 1.11 
RNF180 Q8NBD1 Q86T96 Q0JSU3 Q495A8 NM_178532 0.82 0.71 0.74 0.47  0.31 0.40 
RNF168 Q8NA67 Q8IYW5 Q96NS4 NM_152617 1.21  1.33 1.41  n.a. 0.61  1.02 
ANAPC11 Q9NYG5 Q9P0R2 Q9BW64 Q502X9 
NM_001002244- 
NM_001002248  1.13  1.41 1.96 0.85 1.31 2.21 
PCGF4 P35226 Q96F37 Q16030 NM_005180 2.07  2.12  2.26  0.95 1.24 1.14 
ZNF364 Q9Y4L5 Q7Z2J2 Q5T2V9 NM_014455 2.21 1.18 1.45  n.a. 0.64 0.52  
CGRRF1 Q99675 Q96BX2 NM_006568 0.60  0.62  0.60 n.a. 0.32  0.53  
CHFR 
Q9NRT4 Q96EP1 Q96SL3 Q9NT32 
Q9NVD5 NM_018223 1.04  0.85  n.a.  n.a. 0.43 0.55 
STUB1 Q9UNE7 Q969U2 O60526 Q9HBT1 NM_005861 0.84 0.60 0.59 0.87 1.11  1.79 
RFWD2 Q9H6L7 Q8NHY2 Q6H103 NM_022457 0.94  1.54 0.86  0.70 0.65 0.65  
RNF2 Q99496 Q5TEN1 Q5TEN2 NM_007212 1.19  1.10 1.20 0.50  0.41 0.60  
RNF24 Q9Y225 Q9UMH1 NM_007219 0.59 0.81  0.59 n.a.  0.59  n.a. 
ZNF313 Q9Y508 Q6N0B0 NM_018683 0.62  1.63  1.98  0.91  1.40 1.48  
RNF123 
Q9H0M8 Q5I022 Q8IW18 Q6PFW4 
Q5XPI4 
Q9H9T2 Q71RH0 Q9H5L8 NM_022064 0.84  0.62 0.55  n.a. 0.58 n.a. 
FANCL Q9NW38 NM_018062 1.54  1.33 1.73   n.a. 1.59  n.a. 
PJA1 Q9HAC1 Q8NG27 Q8NG28 NM_022368 0.74  0.72  0.71  n.a.  1.36 2.16 
RNF186 Q9NXI6 Q53GE0 NM_019062 0.11  0.21 0.20  n.a.  0.65  0.54  
RNF167 Q9H6Y7 Q8NDC1 Q9Y3V1 Q6XYE0 NM_015528 0.29  0.50  0.50  0.90  n.a. 1.04  
ZNRF2 Q8NHG8 Q8NEX1 NM_147128 1.36  1.03 1.80 1.07 1.03 0.97  
MKRN2 
Q9NRY1 Q9H000 Q9BUY2 Q8N391 
Q96BD4 NM_014160 1.92  1.18 1.48  1.37  1.12 0.95  
RNF181 Q9P0P0 NM_016494 0.95  1.31  1.20   n.a. 1.01 0.82  
MARCH2 Q9P0N8 Q8N5A3 Q96B78 
NM_001005415 
NM_001005416 
NM_016496 0.59 0.63  0.65  0.49 0.82  0.99 
RNF5 Q99942 Q9UMQ2 NM_006913 1.25 0.82  0.78  1.62 0.76 0.64 
RNF10 Q9ULW4 Q92550 Q8N5U6 Q9NPP8 NM_014868 0.61 0.69 0.63 n.a. 0.83 0.89  
MARCH6 O60337 O14670 Q86X77 NM_005885 1.15  1.72  2.16  1.34  0.70  0.95 
DZIP3 
O75162 Q86Y13 Q6P3R9 Q6PH82 
Q86Y14 
Q86Y15 Q86Y16 Q8IWI0 Q96RS9 NM_014648 1.00 0.58 0.60  n.a.  0.95 1.75  
MYLIP Q9UHE7 Q8WY64 Q9BU73 Q9NRL9 NM_013262 0.93 1.61  2.18 0.90 2.89  n.a. 
MKRN1_1 Q9UEZ7 Q9UHC7 Q9H0G0 Q6GSF1 NM_013446 1.21 0.67  0.95 0.41  1.15 0.93 
SIAH2 O43255 O43270 NM_005067 0.81 0.88  0.92   n.a. 1.25 0.98 
TRIM22 Q15521 Q8IYM9 NM_006074 0.22 0.42 0.30  n.a. 0.25 0.22 
RNF139 O75485 Q7LDL3 Q8WU17 NM_007218 1.82  1.59 1.82  n.a. 1.70  1.54 
Name UniProt/trEMBL RefSeq
B
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6.1 Patient data 
Table 5.2 | NOXA and UCH-L1 expression in melanoma patients. Samples were 
selected from the archives of the University Hospital of Cologne with local research ethics committee 
approval. Melanomas were grouped into one of the four major subtypes according to histopathology 
and positivity to routinely analysed melanoma markers, HMB45 and S100. The 81 samples comprise 
these major subtypes, 22 superficial spreading malignant melanomas (SSM), 15 nodular melanomas 
(NMM), 1 lentigo maligna melanomas (LMM), 2 acral lentiginous melanomas (ALM), but also 40 
cutaneous and 1 brain melanoma metastasis.  
Intensities of specific staining in tumour cells were arbitrarily set as the following: -, no expression; +, 
low expression; ++, moderate expression; +++, strong expression. 
 
 
Sex 
      Patient ID M(1) W (0) Age (Y)   pathology localizazion TD Noxa UCHL1 
1 1 74 met trunk  -  +++  - 
2 1 31 met rectal tag  -  ++  - 
3 1 82 met extremity  -  +++  + 
4 1 73 met extremity  -  ++  - 
5 1 27 met extremity  -  ++  - 
6 0 78 met trunk  -  +  - 
7 1 62 met extremity  -  ++  - 
8 0 61 met extremity  -  ++  - 
9 1 70 met trunk  -  +  - 
10 0 79 met face  -  -  - 
11 0 78 met face  -  -  - 
12 1 79 met face  -  ++  + 
13 1 73 met trunk  -  +++  - 
14 1 78 met n.i.  -  +  + 
15 0 64 met n.i.  -  ++  + 
16 0 44 met n.i.  -  +  - 
17 0 57 met n.i.  -  ++  + 
18 1 42 met n.i.  -  ++  + 
19 1 83 met trunk  -  ++  - 
20 1 52 met inguinal  -  +++  ++ 
21 0 82 met n.i.  -  -  - 
22 1 54 met n.i.  -  -  - 
23 0 77 met n.i.  -  ++  - 
24 1 83 met n.i.  -  +  - 
25 1 56 met n.i.  -  -  - 
26 0 44 met n.i.  -  -  - 
27 1 72 met n.i.  -  +  - 
28 0 78 met n.i.  -  +  - 
29 1 60 met n.i.  -  ++  - 
30 1 73 met n.i.  -  +  + 
31 1 43 met n.i.  -  ++  + 
32 1 12 met n.i.  -  ++  - 
33 0 79 met face  -  +  - 
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34 1 73 met n.i.  -  ++  + 
35 1 62 met trunk  -  +++  - 
36 0 64 met n.i.  -  +++  - 
37 0 77 met n.i.  -  ++  - 
38 1 44 met extremity  -  ++  - 
39 0 37 met brain  -  +++  ++ 
40 1 70 met trunk  -  +++  + 
41 1 70 met extremity  -  ++  - 
42 0 81 LMM foot 0,78  +++  - 
43 0 69 SSM trunk 4,05  ++  + 
44 1 58 NMM extremity 2,41  +++  - 
45 1 34 SSM trunk 4,80  +  - 
46 1 59 SSM trunk 0,96  ++  - 
47 1 72 SSM extremity 1,94  ++  - 
48 0 40 NMM extremity 2,80  +++  - 
49 1 39 NMM trunk 5,10  +++  - 
50 0 81 NMM extremity 3,40  +  - 
51 1 77 SSM extremity 13,91  ++  + 
52 1 76 SSM trunk 1,33  ++  - 
53 1 50 SSM trunk 1,51  ++  - 
54 1 36 SSM trunk 0,52  +  - 
55 1 40 NMM extremity 0,44  -  - 
56 0 82 NMM extremity 2,34  +++  - 
57 1 79 NMM nuchal  6,67  ++  + 
58 0 71 NMM foot 4,92  +++  - 
59 1 72 NMM extremity 4,70  +++  - 
60 0 78 NMM extremity 19,50  +++  + 
61 1 49 NMM foot 9,53  +++  + 
62 1 54 SSM trunk 3,74  +++  + 
63 1 46 SSM trunk 3,20  -  - 
64 0 55 SSM extremity 0,65  +++  - 
65 1 72 SSM extremity 1,28  ++  - 
66 1 81 SSM extremity 1,45  -  + 
67 1 69 SSM trunk 3,13  +  - 
68 0 80 SSM face 6,15  +++  - 
69 1 75 SSM trunk 1,04  +  - 
70 0 58 NMM vulva 14,00  ++  + 
71 1 76 NMM trunk 3,60  ++  - 
72 1 41 NMM trunk 8,36  +++  + 
73 1 79 SSM extremity 5,45  +++  + 
74 0 82 SSM, rectal tag 1,33  ++  - 
75 1 56 SSM trunk 4,25  +++  ++ 
76 1 62 SSM extremity 2,84  +  + 
77 0 79 ALM extremity 4,22  +  - 
78 0 75 SSM trunk 3,80  ++  - 
79 1 68 SSM trunk 3,05  ++  + 
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80 0 88 ALM toe 2,89  +  - 
81 1 79 NMM n.i. n.i.  +  - 
N. i.  not indicated 
Met cutaneous metastasis 
LMM Lentigo Maligna Melanoma 
ALM Acral Lentiginous Melanoma 
SSM Superficial Spreading Melanoma 
NMM  Nodular Malignant Melanoma 
 
 
 
Table 5.3 | NOXA and UCH-L1 expression in colorectal carcinoma patients. 
Intensities of specific staining in tumour cells were arbitrarily set as the following: -, no expression; +, 
low expression; ++, moderate expression; +++, strong expression. 
 
 
Sex 
 
UICC 
      Patient ID M(1) W (0) Age (Y) Stage T N M  Grade NOXA UCH-L1 
8 0 65 2 3 1 0 2 ++ - 
10 1 65           ++ - 
15 1 78 2 3 0 0 2 + - 
16 1 77 3 3 2 0 3 + - 
17 1 74 2 3 0 0 2 +++ + 
19 0 72 2 3 0 0 2 + - 
20 1 65 4 3 0 1 2 ++ - 
21 1 64 4 3 1 1 2 + - 
26 0 72 3 3 2 0 2 +++ + 
28 1 62 3 4 2 0 3 ++ - 
33 0 74 3 3 2 0 2 ++ + 
34 1 64 4 3 2 1 2 +++ + 
35 1 76 2 3 0 0 2 ++ - 
36 1 67 1 2 0 0 2 + - 
37 0 82 2 3 0 0 2 ++ - 
38 0 59 2 3 0 0 2 + - 
46 0 65 2 4 0 0 3 + - 
48 0 83 4 4 0 1 3 ++ - 
55 1 73 3 3 1 0 2 +++ + 
74 1 67 2 3 0 0 2 +++ + 
76 1 68 2 3 0   2 ++ + 
79 1 70 3 3 1 0 2 ++ - 
80 1 68 2 3 0 0 2 +++ ++ 
88 1 76 4 4 1 1 3 ++ + 
91 0 62 2 3 0 0 2 - - 
T1-4:  size and/or extension of the primary tumor 
N:  degree of spread to regional lymph nodes 
N0: tumor cells absent from regional lymph nodes 
N1:  regional lymph node metastasis present; (at some sites: tumor spread to closest or small 
 number of regional lymph nodes) 
N2:  tumor spread to an extent between N1 and N2 
M:  presence of metastasis 
M0:  no distant metastasis 
M1:  metastasis to distant organs (beyond regional lymph nodes) 
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6.2 Vector maps 
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